American University in Cairo

AUC Knowledge Fountain
Theses and Dissertations

Student Research

2-1-2014

Identification of T-cell epitopes in the Hepatitis C virus genotype 4
proteome: a step towards epitope-driven vaccine development
Karim Mohamed Ali Abdel-Hady

Follow this and additional works at: https://fount.aucegypt.edu/etds

Recommended Citation

APA Citation
Abdel-Hady, K. (2014).Identification of T-cell epitopes in the Hepatitis C virus genotype 4 proteome: a step
towards epitope-driven vaccine development [Master's Thesis, the American University in Cairo]. AUC
Knowledge Fountain.
https://fount.aucegypt.edu/etds/1172

MLA Citation
Abdel-Hady, Karim Mohamed Ali. Identification of T-cell epitopes in the Hepatitis C virus genotype 4
proteome: a step towards epitope-driven vaccine development. 2014. American University in Cairo,
Master's Thesis. AUC Knowledge Fountain.
https://fount.aucegypt.edu/etds/1172

This Master's Thesis is brought to you for free and open access by the Student Research at AUC Knowledge
Fountain. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of AUC
Knowledge Fountain. For more information, please contact thesisadmin@aucegypt.edu.

The American University in Cairo
School of Sciences and Engineering

IDENTIFICATION OF T-CELL EPITOPES IN THE HEPATITIS C
VIRUS GENOTYPE 4 PROTEOME: A STEP TOWARDS EPITOPEDRIVEN VACCINE DEVELOPMENT
A Thesis Submitted to
The Biotechnology Graduate Program

in partial fulfillment of the requirements for
the degree of Master of Science

by Karim Mohamed Ali Abdel-Hady

under the supervision of
Prof. Hassan M.E. Azzazy
Dr. Anne S. De Groot

Fall 2013

The American University in Cairo

IDENTIFICATION OF T-CELL EPITOPES IN THE HEPATITIS C
VIRUS GENOTYPE 4 PROTEOME: A STEP TOWARDS EPITOPEDRIVEN VACCINE DEVELOPMENT
A Thesis submitted by
Karim Mohamed Ali Abdel-Hady
to the Biotechnology Graduate Program
Fall 2013
in partial fulfillment of the requirements for
the degree of Master of Science in Biotechnology
has been approved by:
Prof. Hassan M.E. Azzazy
Thesis Committee Chair and Thesis Supervisor
Affiliation: Professor of Chemistry, School of Sciences and Engineering, the American
University in Cairo.
Date ____________________
Dr. Anne S. De Groot
Thesis Co-Supervisor
Affiliation: Research Professor and Director, Institute for Immunology and Informatics,
University of Rhode Island.
Date ____________________
Dr. Ahmed Moustafa
Thesis Committee Inernal Examiner
Affiliation:
Date ____________________
Dr. Aishaa Yaseen Abdel-Ghafaar
Thesis Committee External Examiner
Date ____________________

Dr. Asma Amleh
Thesis Committee Moderator
Date ____________________

ii

ACKNOWLEDGEMENTS
I would like to express my sincerest gratitude and appreciation to my advisor,
Prof. Hassan Azzazy, who was not only my teacher and mentor through out this journey
to attain the Master of Science degree, but also like a father to me. I thank him for the
science he taught me, for teaching me how to become a good researcher, for encouraging
me to seize every learning opportunity that would boost my future career, and for
inspiring me to direct my professional efforts for the good of mankind. His support and
belief in my capabilities motivated me to put my best efforts into completing this project
and gave me a promising outlook for my future career. I will forever be privileged to
have been one of his students.
I would also like to extend my deepest thanks to my co-advisor, Dr. Anne De
Groot, whose support and guidance were pivotal in completing this project. I thank her
for welcoming me into the University of Rhode Island to attend the 2012 Neglected
Tropical Diseases workshop, where I acquired the scientific and technical knowledge that
formed the basis for this project, and where I performed part of the project’s empirical
analysis. I sincerely thank her for her continuous support and encouragement, and for
sparing no effort at providing me with the help I need to complete this project.
A special thank you to my teammates at the Novel Diagnostics and Therapeutics
research group at the American University in Cairo for their help, support, and
encouragement; especially to Marwa Hussein for her great help and technical advice. I
would also like to thank my colleague, Ms. Nahla Hussein, for providing me with very
useful technical advice on the optimization of the Polymerase Chain Reaction performed
in this project.
I would also like to express my gratitude to Frances Terry and Sheila Chandran
from Dr. Anne De Groot’s team at EpiVax Inc., who were always there to help me with
the immunoinformatics analysis part of this project in spite of their busy schedules. I
would also like to thank Andres Gutierrez, Dr. Anne’s graduate student, for assisting me
with the immunoinformatics analysis at the start of this project, and Mr. Joe Desrosiers,
from Dr. Anne’s team at the Institute for Immunology and Informatics at the University
of Rhode Island, for assisting me in performing the empirical validation of part of the
results of the immunoinformatics analysis performed in this project.
Last but not least, I would like to sincerely thank my family for their guidance and
support that lead me to this point; especially my mother, who motivates me to be my best
in life, and who has also inspired me to tackle the subject of this project. Special thanks
to my sister, Lana Abdel-Hady, for assisting with the artwork in this project.

iii

ABSTRACT
The American University in Cairo

IDENTIFICATION OF T-CELL EPITOPES IN THE HEPATITIS C
VIRUS GENOTYPE 4 PROTEOME: A STEP TOWARDS EPITOPEDRIVEN VACCINE DEVELOPMENT
BY: Karim Mohamed Ali Abdel-Hady
Under the Supervision of Prof. Hassan M.E. Azzazy and Dr. Anne S. De Groot

Hepatitis C is an inflammatory infectious disease of the liver caused by the Hepatitis C
Virus (HCV). It is a global pandemic, chronically inflicting 150 million people
worldwide, with millions of new infections arising annually. The standard therapy of
HCV is expensive, associated with severe side effects, and has variable success rates.
Thus far, no HCV vaccine has been developed, owing to the challenges that faced and
still face its development. Despite these challenges, several attempts have been taken to
develop a vaccine, some of which have progressed to phase II clinical trials. Most of
these attempts, however, have focused on HCV genotypes 1 and 2 as vaccine targets, and
almost no attention has been given to HCV genotype 4 (HCV-4), the viral genotype most
prevalent in the Middle East and Central Africa. In an attempt to fill this gap in HCV-4
vaccine research, this project describes the in silico identification of a group of highly
conserved and immunogenic T-cell epitopes from the HCV-4 proteome, using the iVAX
immunoinformatics toolkit (EpiVax Inc., RI, USA), as a first step towards the
development of an epitope-driven vaccine against the viral genotype. Furthermore, it puts
forth a fast and inexpensive method for the validation of the results retrospectively using
the repository of empirical HCV immune epitope data on the Immune Epitope Database
(IEDB). 90 HLA class I and 14 HLA class II epitopes were identified. From those, 20
HLA class I epitopes were found to be previously uncharacterized, while the in silico
HLA binding predictions for 27 others (class I and class II) have been retrospectively
validated. The retrospective validation results for 4 of the identified HLA class II
epitopes were confirmed by a pilot HLA class II binding assay. Furthermore, an
investigation of the conservancy of a selected set of the identified epitopes in newly resequenced HCV strains from the Egyptian population was performed. The identified and
retrospectively validated set of epitopes constitutes a good target for further
immunogenicity testing and epitope-driven vaccine development against HCV-4.
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1. INTRODUCTION
Hepatitis C is an infectious inflammatory liver disease caused by the Hepatitis C
virus (HCV); a blood-borne virus transmitted mainly through the percutaneous route
from an infected to a healthy individual. According to the World Health Organization
(WHO), approximately 150 million people suffer from chronic HCV infection
worldwide, with 3-4 million newly infected each year. Around 350,000 patients die each
year as a result of HCV-related diseases [1]. There are six major genotypes of the virus
whose distribution and prevalence varies widely between different regions and countries
[2]. Global infection rates peak in Egypt, where 22% of the population is chronically
infected, and an estimate of 500,000 get newly infected each year [1,3]. Over 90% of the
Egyptian patients are infected with HCV genotype 4 (HCV-4), the most prevalent
genotype in the Middle East and Central and Western Africa [4-6]. The high prevalence
of HCV in Egypt has been attributed to the use of contaminated needles in an
antischistosomal therapy campaign that took place in the 1950s [4-7]; and currently, the
main route of transmission is through clinical procedures in which improperly sterilized
instruments are utilized [4,6].
Apart from the percutaneous route of transmission, HCV transmission can also
occur through sexual and perinatal exposures; these routs of transmission, however, are
much less efficient and are not major contributors to new infections [8]. Following the
onset of infection, the disease starts with an acute phase that lasts for about 6 months.
During that phase, 15-30% of the patients are able to clear the virus spontaneously;
however in 70-85% of the patients the virus manages to evade the host’s immune system
and persist, leading to the progression of the disease to a chronic phase. The chronic
phase can last for decades, eventually culminating in liver cirrhosis and/or hepatocellular
carcinoma for 5-20% of the chronically infected patients and death for 1-5% of the
patients [1,9,10].
HCV is an enveloped RNA virus belonging to the Hepacivirus genus of the
family Flaviviridae. Its genome consists of a single sense RNA strand of an approximate
size of 9600 bases; harboring a single open reading frame (ORF) that is flanked by 5’ and
1

3’ untranslated regions (UTR). The ORF (also known as the polyprotein gene) is
translated into a precursor polyprotein molecule approximately 3000 amino acids in size.
This molecule is processed during and after its synthesis via viral and host cellular
machinery into 10 viral proteins, divided into 3 structural and 7 non-structural
(functional) proteins (Table 1) [11]. HCV replicates via a viral RNA-dependant-RNA
polymerase known as Non-Structural protein 5B (NS5B). The enzyme lacks the proofreading capability normally present in DNA polymerases, causing the virus to experience
a very high mutation rate upon replication of approximately 0.0014 to 0.0019 mutations
per nucleotide per year [11,6]. This high rate of mutation is one of the main mechanisms
by which the virus manages to evade the host’s adaptive immune system; furthermore, it
results in the diversification of the virus into a wide array of genetic variants. These
variants are classified based on the extent of genetic variation into genotypes, varying by
30-33% of the genome, subtypes, varying by 20-25% of the genome, and quasi-species
within each patient that may vary from a single point mutation up to 10% or more of the
genome [2,11]. HCV primarily infects and replicates in liver hepatocytes of human and
chimpanzee hosts only [12]. Reports also indicate that it is able to infect some peripheral
blood mononuclear cells such as B-cells and dendritic cells (DCs); however it does not
replicate within those cells [13].
After the virus infects the liver hepatocytes and commences replication, the
host’s innate immune system in response attempts to protect the healthy liver hepatocytes
from infection and kill the infected ones by the actions of Interferons (IFNs) and Natural
Killer (NK) cells. The adaptive immune response that is later initiated involves
neutralizing antibodies that may block viral entry into healthy hepatocytes, and the killing
of the infected hepatocytes by the action of the CD8+ cytotoxic T-cells [13-15]. Although
in 15-30% of the patients the immune system manages to spontaneously clear the virus,
in the majority of the patients the virus manages to evade the immune system by several
mechanisms; leading to the persistence of infection. Chief amongst those mechanisms is
the highly mutable nature of the virus, which allows for the production of escape variants
that evade recognition by the cells of the adaptive immune system. Other mechanisms
include inhibition of type I IFN production, induction of T-cell exhaustion, and induction
regulatory T-cell action [13,14]. The outcome of HCV infection (spontaneous clearance
2

or persistent infection) is believed to be determined by the strength and nature of the
immune response during the acute phase of the infection. A strong base of evidence
demonstrates that a strong, multi-specific and sustained T-cell response to the virus is
associated with viral clearance. On the other hand, a weak, narrow, and short-lasting Tcell response is associated with viral persistence. The role of neutralizing antibodies in
HCV clearance is debatable, while studies show an association between a rapidly-induced
production of high titers of cross-neutralizing antibodies and spontaneous HCV
clearance; others have shown that viral clearance is possible in the absence of anti-HCV
neutralizing antibodies [13,15].
The standard treatment regimen for HCV infection is a combination therapy of
pegylated IFN alpha and ribavirin. The aim of treatment is to achieve a sustained
virological response (SVR); defined as the absence of HCV RNA from the patient’s
blood 24 weeks after the cessation of treatment. This treatment, however, is costly,
causes severe side effects, and does not guarantee the elimination of infection [10].
Recently, with the advent of protease inhibitor direct-acting antiviral drugs (e.g.Telaprivir
and Boceprivir), the optimum treatment regimen for HCV genotype 1 infection has been
altered to include a protease inhibitor in a triple therapy with pegylated IFN alpha and
ribavirin. This new regimen increases the chances of achieving SVR for genotype 1
infected patients; however it is still expensive, has associated side effects (e.g. dysgeusia,
severe fatigue, debilitating depression, and hemolysis), and is less effective for treating
infections with other HCV genotypes such as genotype 4 [16]. The high costs, significant
side effects, and uncertainty in achieving SVR associated with HCV therapy warrant
support for the development of an HCV vaccine, a goal that so far has not been achieved
[17].
On top of the persisting challenge of overcoming the various mechanisms by
which the virus evades the immune system, HCV vaccine development was hampered by
other technical obstacles. Due to the fastidious nature of the virus, HCV could not be
produced in tissue culture systems nor was there a readily available animal model of
infection for it. The gap created by the lack of cell culture systems was filled by the
development of HCV pseudo type particles (HCVpp) in 2003, and then in 2005 the first
3

tissue culture system of infection was developed [18]. This allowed for the identification
of the receptors used by the virus for cell entry; which allowed for the production of
humanized mouse models expressing those receptors. These models are still early in
development; however their availability could accelerate preclinical vaccine testing
[17,19]. In spite of those challenges, several vaccine studies have been conducted on
animal models in the past decade yielding promising results; a small number of which
have actually progressed to human phase II clinical trials.
As aforementioned, HCV-4 is highly prevalent in the Middle East and Central and
Western Africa and is increasingly spreading to countries in Southern and Western
Europe and to North America with increasing immigration and travel [20]. In Egypt,
more than 90% of HCV patients are infected with HCV-4; more than 500,000 new
infections are estimated to occur in Egypt annually [3,5,7]. Despite the direness of the
situation, very little attention has been given to the development of therapies and vaccines
for HCV-4. According to a meta-analysis study performed on all the existing HCV
epitope data on the Immune Epitope Database (IEDB) (a repository of immune epitope
data manually curated from reported peer reviewed literature, patents, and direct
submissions from companies and institutions [21]), only 13 epitopes for HCV genotypes
4, 5, and 6 combined were reported out of 3444 unique reported HCV epitopes that tested
positive in T-cell and B-cell assays [22]. In an attempt to fill this wide gap in HCV-4
immune epitope research, and to address the un-tackled subject of HCV-4 vaccine design,
this project aims to identify, in silico, a set of highly immunogenic and conserved T-cell
epitopes from within the HCV-4 proteome as targets for an epitope-driven vaccine for
HCV-4. The epitopes were identified using the validated immunoinformatics iVAX
toolkit (EpiVax Inc., RI, USA), a suite of immunoinformatics tools that can be used for
the in silico design of epitope-driven vaccines derived from protein sequences of interest
[23]. This project also describes a fast and inexpensive method for the retrospective
validation of the in silico results using the repository of HCV immune epitope data on the
IEDB, which can accelerate and cut-down the expenses of the development of the
vaccine.
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2. LITERATURE REVIEW
2.1

The Life Cycle of HCV
The HCV life cycle begins with the entry of the virus into the liver hepatocytes. In

the blood, HCV circulates in both free and bound forms; where it can be associated with
low density lipoproteins (LDL), very low density lipoproteins (VLDL), and
immunoglobulins [12,24,25]. Once the virus reaches the liver, its entry into the
hepatocytes is mediated by the attachment of the membrane-bound viral E1-E2
heterodimer (formed by the dimerization of the HCV structural proteins E1 and E2) to
hepatocyte cell-surface molecules and receptors; these include CD81, a tetraspanin
protein expressed on the surface of several cell types, and Scavenger Receptor class B
type I (SR-BI), a glycoprotein whose natural ligand is high density lipoproteins (HDL).
Also among those molecules and receptors are the Low Density Lipoprotein receptor
(LDLR), the tight junction protein Claudin-1 (CLDN-1), glycosaminoglycans (GAG),
and others. Although further investigation needs to be carried out, studies show that LDL
receptors together with glycosaminoglycans may act as the primary collectors of HCV
particles from the blood stream for further targeting to other HCV receptors such as
CD81. Studies show that CD81 and SR-BI are both necessary but not sufficient for viral
entry [12,25]. The tight junction protein CLDN-1 was found to be an essential coreceptor acting at a later stage of the entry process after the virus has interacted with CD81. However, like CD81 and SR-BI, it was found insufficient (when co-expressed with
CD81 and SR-BI) for mediating viral entry [12]; meaning that there are other molecules
required for the completion of the process. Following attachment, HCV enters the cell
via Clathrin-dependent endocytosis. The low pH-environment inside the endosome
induces the fusion between the viral and endosomal membranes; which is followed by the
release of the viral nucleocapsid into the cytoplasm [12,25]. Figure 1 schematically
represents the viral entry step of the HCV life cycle as it is currently understood.
After the release of the nucleocapsid into the cytoplasm, the single sense genomic
RNA strand of HCV is released, and serves as the messenger RNA for the synthesis of
the viral precursor polyprotein molecule. The translation of the RNA strand is controlled
5

by an Internal Ribosomal Entry Site (IRES), spanning domains II, III, and IV of the
5’UTR (Figure 2) and the first 24-40 nucleotides of the region coding for the Core
structural protein. The IRES mediates the initiation of cap-independent translation of the
polyprotein gene. [12,25]. After the synthesis of the polyprotein molecule is initiated, the
molecule is directed to the Endoplasmic Reticulum (ER) mediated by an internal signal
peptide located between the amino acid sequences of the Core and E1 structural proteins;
this sequence is responsible for mediating the translocation of the ectodomain of the E1
protein into the ER lumen. At the ER, the polyprotein molecule is processed via host and
viral enzymes during and after its synthesis into the structural and non-structural proteins
of HCV. First, the three structural proteins (Core, E1, and E2) and the non-structural
protein p7 are processed via host ER signal peptidases. The remaining 6 non-structural
proteins, namely NS2, NS3, NS4A, NS4B, NS5A, and NS5B, are processed via the cisacting viral auto-protease NS2-3, and the cis and trans acting NS3-NS4A protease. First,
the NS2-3 cis-acting auto-protease cleaves the bond between the NS2 and NS3
polypeptides in the polyprotein chain [12,26]. Then, the NS3 protease with the NS4A
protein as its co-factor catalyzes cis-cleavage of the NS3/NS4A junction and the transcleavage of the NS4A/NS4B, NS4B/NS5A, and NS5A/NS5B junctions. The processed
structural and non-structural proteins become associated with the ER membrane [12,25].
Figure 2 represents schematically the relative positions of the amino acid sequences of
the HCV structural and non-structural proteins in the precursor polyprotein sequence, and
figure 3 schematically represents the 3D structures of the proteins and their associations
with the ER membrane.
Similar to all positive-strand RNA viruses, HCV RNA replication takes place at a
membrane-associated replication complex composed of replicating RNA, viral proteins,
and rearranged cellular membranes. The site of HCV RNA replication in the cell is called
the membranous web; the name given to a specific alteration of the ER whose formation
is induced by the NS4B viral protein alone. At the membranous web, HCV RNA
replication is catalyzed by the RNA-dependant RNA polymerase NS5B in a two-step,
semiconservative, and asymmetric process. In the first step, the positive RNA strand
serves as a template for the synthesis of an intermediate negative RNA strand. The
negative strand is then used as a template in the second step for the synthesis of several
6

positive RNA strands; which will later be used for precursor polyprotein synthesis, the
synthesis of new negative RNA strand intermediates, and for packaging into new virions
for release from the cell. Both steps of the replication process are catalyzed by NS5B.
The replication process is modulated by the fluidity of the membranous web which is
dictated by the degree of saturation of its fatty acid component molecules; where the
abundance of cholesterol and saturated fatty acids stimulates viral replication and that of
poly-unsaturated fatty acids inhibits it [12, 25,26].
Following viral RNA replication and protein synthesis, the newly synthesized
positive RNA strands are packaged into new viral particles which are later released from
the cell. According to available evidence, this packaging process is most likely initiated
by the interaction of the newly synthesized positive RNA strands with the Core viral
proteins, which in themselves are capable of self-assembly in order to form the
nucleocapsid. Virions are then presumably formed by budding into the ER lumen or that
of an ER-derived compartment; where they are then released from the cell via the
constitutive secretory pathway [12, 25,26].

2.2

Immunity to HCV

2.2.1 Effector Mechanisms of the Host Immune Response:
2.2.1.1 Innate Immunity - Interferons
Immediately after HCV infects the liver hepatocytes, the host’s innate immune
system attempts to combat the infection mainly via the actions of IFNs and NK cells.
Interferons are a family of secreted cytokines that act in autocrine and paracrine manners
to stimulate intracellular networks that modulate mechanisms of resistance to viral
infections, enhance and shape innate and adaptive immune responses, and regulate the
survival and death of normal and cancerous cells [27]. They are categorized based on
their cell-surface receptors into three types: type I, type II, and type III. Despite their
structural and genetic differences, type I and III Interferons share identical induction
mechanisms, signal transduction pathways, and biological actions; where they both
induce antiviral activity in their target cells [28]. Type I IFNs are structurally subdivided
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into IFN-β and several subtypes of IFN-α; they can be expressed in most body cell types,
and their receptor is similarly widely expressed. Type III IFNs, also known as λ
interferons, are divided into 3 subtypes namely IFN-λ1, IFN-λ2, and IFN-λ3, which are
otherwise known as interleukin (IL)-29, IL-28A, and IL-28B respectively; they are
expressed in several –but not all- cell types. In contrast to type I and type III Interferons,
the type II interferon, comprised in a single molecule denoted IFN-γ, is expressed only in
NK cells and activated T-cells, and possesses mainly immunomodulatory actions [29,30].
IFN-γ will be discussed in more detail later in this section within the context of NK cell
and T-cell response mechanisms.
The production of type I interferons is most potently stimulated by viral
infections; specifically by the double-stranded RNA intermediates produced during the
replication of viruses such as HCV [29,31]. After their production, type I interferons
induce antiviral responses in their target cells by binding to a heterodimeric cell-surface
receptor called the Interferon-α/β receptor (IFNAR), which is composed of two subunits,
namely IFNAR1 and IFNAR2. The binding of the interferons to the receptor causes its
subunits to dimerize, activating a Janus Kinase-Signal Transducer and Activator of
Transcription (JAK/STAT) signal transduction pathway. The activation of the pathway
culminates in the activation of transcription of a set of genes, known as the Interferon
Stimulated Genes (ISG), whose protein products act by inhibiting viral replication in the
cell. This protects paracrine-induced uninfected cells from infection, and limits the spread
of the virus from the autocrine-induced infected cells [29,31]. In addition to inhibiting
viral replication, type I IFNs also promote adaptive cell-mediated immunity against
intracellular microbe infections by increasing the expression of class I Major
Histocompatibility Complex (MHC) molecules on the surface of the infected cells. They
also stimulate the development of CD4+ TH1 helper T-cells, and enhance the effector
functions of NK cells as will be explained later [31].
Similar to type I IFNs, the production of type III IFNs is also stimulated by viral
infections. Studies show that both types of IFNs are co-produced upon induction with all
the inducers that were investigated; suggesting that they are both regulated by the same
mechanism [28]. Upon binding to their receptor, type III IFNs also activate a JAK/STAT
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signaling pathway that culminates in the activation of transcription of a set of ISGs
similar to those activated by type I IFNs; thereby also inhibiting viral replication in
paracrine and autocrine manners. However, the heterodimeric cell-surface receptor to
which type III IFNs bind is different, where it is composed of two polypeptide chains
called IFNLR1 and IL10R2. This receptor is not expressed as broadly as the IFNAR
receptor on different body cells, however it is expressed in liver hepatocytes [28,29].
Studies show that ISGs are generally highly expressed in the livers of HCVinfected patients [29,30]. Available cell culture studies indicate that HCV pathogen
associated molecular patterns (PAMPs) responsible for the induction of IFN production,
which include double-stranded RNA (dsRNA) and viral proteins, are identified by the
PAMP receptors Retinoic acid-inducible gene I (RIG-I) and the Toll-like receptor 3
(TLR3); the PAMP receptors TLR2 and TLR7 may also be implicated in HCV detection
[30]. RIG-I is a cytoplasmic RNA helicase that senses non-self, short dsRNA or ssRNA
with a free 5’-triphosphate moiety. Toll-like receptors, in general, are membrane-bound,
mainly endosomal receptors; TLR3 senses dsRNA and viral DNA, TLR2 senses certain
viral proteins, and TLR7 (mainly expressed in plasmacytoid dendritic cells) senses
ssRNA. Following HCV detection, these receptors trigger signal transduction pathways
that induce the expression of type I and III IFNs, which are then secreted to induce the
expression of ISGs in paracrine and autocrine manners. An example of the ISGs
expressed in HCV infection is the IFN-stimulated gene 20-kDa protein (ISG20), whose
protein product is a 3′–5′ exonuclease that suppresses viral replication by targeting
ssRNA. Another example is the 2’–5’ oligoadenylate synthetase (OAS) enzyme gene,
whose protein product catalyzes the synthesis of 2’-5’-oligoAdenylic acid, which in turn
activates a latent endoribonuclease called RNase-L. RNase-L catalyzes the degradation of
viral ssRNA as well as cellular mRNA and rRNA thereby globally inhibiting protein
synthesis in the cell and triggering its apoptosis [29,30]. The production of type I and III
IFNs triggered by HCV is depicted in detail in figure 4.
2.2.1.2 Innate Immunity – Natural Killer Cells
In addition to the antiviral actions of IFNs, NK cells combat HCV infection by
triggering the apoptosis of infected hepatocytes, thereby preventing the production and
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spread of new HCV virions to healthy hepatocytes. NK cells are a subset of lymphocytes
belonging to the T-cell lineage that recognize and kill pathogen-infected cells, cancer
cells, and cells not expressing self MHC class I molecules, without the need for prior
sensitization like that required by the T and B cells of the adaptive immune system
[31,32]. Their activation is regulated by a balance between signals produced from
activating and inhibitory receptors expressed on their surface. The inhibitory receptors
bind to self-MHC class I molecules normally expressed in all body cells independent of
the T-cell epitope that these molecules are presenting in their binding clefts. The
activating receptors bind to pathogen-derived molecules (proteins and carbohydrates) or
non-classical MHC molecules that are expressed/upregulated on the surface of infected,
cancerous, or otherwise stressed body cells. Usually if the inhibitory receptors are
engaged, the NK cell is not activated due to the dominance of the inhibitory signal. If
however the inhibitory receptors are not engaged due to the absence of enough normal
self-MHC I molecules on the surface of the target cell, and at the same time the activating
receptors are engaged to their target ligands, the NK cell then becomes activated [31,32].
It is important to note, however, that if several activatory signals are generated at once,
they can collectively overwhelm the inhibitory signal and activate the cell. Furthermore,
in some cases, the engagement of even one activatory receptor may be enough to override
the inhibitory signal and activate the cell [32].
Following activation, NK cells induce apoptosis in their target cells. One way by
which that happens is via enzymes called Granzymes, which enter the target cells through
pores in their membrane created by a protein called Perforin. Both Perforins and
Granzymes are stored in granules in the cytoplasm of NK cells, and are released upon the
cell’s activation. In addition, activated NK cells secrete IFN-γ [31,32]. IFN-γ performs its
biological actions via binding to a dimeric receptor that is ubiquitously expressed on all
nucleated cells called the IFN-γ receptor (IFNGR) [27]. Upon binding, IFN-γ triggers a
JAK/STAT signaling pathway that culminates in the expression of a set of ISGs that are
overlapping with –but not identical to- the ones induced by type I and III IFNs. In innate
immunity, similar to type I and III IFNs, IFN-γ possesses direct antiviral activity, where
it induces the expression of ISGs that inhibit viral replication in its target cells (e.g. 2’–5’
oligoadenylate synthetase (OAS) and Protein Kinase R (PKR)). It also serves as a
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modulator, where it activates macrophages to kill phagocytosed microbes and stimulates
the cytotoxic activity of NK cells [33]. In addition to its functions in innate immunity,
IFN-γ also enhances MHC-associated antigen presentation and recognition during the
cellular adaptive immune response via stimulating the expression of both classes of MHC
molecules, co-stimulatory molecules on Antigen Presenting Cells (APCs), and
intracellular proteins implicated in antigen processing [31-33].
In acute HCV infection, studies show that NK cells in peripheral blood increase in
number and become activated; up-regulating the expression of the activatory receptor
NKG2D, and down-regulating the expression of inhibitory receptor NKG2A.
Furthermore, the levels of IFN-γ produced from the NK cells and their cytotoxicity was
shown to be higher than their counterparts in healthy controls [34]. In the chronic phase
of the infection, generally, the number and function of NK cells are down-regulated. The
decrease in NK cell number could be attributed to the decrease/lack of IL-15 produced by
DCs, the interleukin that is essential for NK cell development and functionality.
However, it could also be due to the compartmentalization of NK cells away from the
peripheral blood stream (the site which early studies concerning the subject have
concentrated on in their analysis). The down-regulation in NK cell function is reflected in
the decrease in their IFN-γ producing activity and their ability to activate DCs [34,35].
Furthermore, NK cells exhibit an increase in IL-10 and TGF-β production; producing an
immunosuppressive environment that encourages viral persistence [33]. Despite this
down-regulation in number and cytokine-secreting function, the natural cytotoxic
functionality of NK cells appears to be intact or increased. This could be explained by the
fact that there are activatory receptors that are up-regulated on their surface during the
chronic phase of the infection (e.g. NKp30, NKp44 and NKp46) [34].
2.2.1.3 Innate Immunity – Other Mechanisms
In addition to the actions of IFNs and NK cells, the production of other
inflammatory cytokines and chemokines is also induced in the HCV-infected liver; which
are also important mediators bridging the innate and adaptive immune responses, and are
critical for T-cell homing to the infected liver. Examples of chemokines produced in the
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liver during HCV infection are the C-C chemokine receptor type 5 (CCR5) ligands:
Chemokine (C-C motif) ligand 3 (CCL3) and CCL5, and the Chemokine (C-X-C motif)
receptor 3 (CXCR3) ligands: Interferon gamma-induced protein 10 (IP-10) and
Chemokine (C-X-C motif) ligand 9 (CXCL9). Studies have shown that there is a
correlation between the levels of some of those chemokines in the blood of HCV patients
and the outcome of infection or the severity of liver inflammation [29].
The innate immune response to HCV buys time for the development of the
adaptive immune response to the virus, in addition to being an important factor in
shaping the later [29]. Unlike the innate immune response, triggering the cells of adaptive
immune system, the B and T lymphocytes, requires the specific recognition of viral
antigens. Adaptive immunity is divided into humoral immunity, and cell mediated
immunity (CMI). Humoral immunity targets extracellular pathogens via antibodies, the
antigen receptors and effector molecules of B-cells, whereas CMI targets intracellular
pathogens via the Cytotoxic actions of CD8+ T-lymphocytes [36].
2.2.1.4 Adaptive Immunity – Cell Mediated Response
CMI is the effector response of T-lymphocytes against microbes that infect nonphagocytic cells and those that survive within phagocytes of phagocytic cells. The best
defined functional populations of T-lymphocytes involved in the CMI response are the
helper CD4+ T-cells, which play an essential role in stimulating and coordinating the
adaptive immune response (both humoral and cellular), and the cytotoxic CD8+ Tlymphocytes (CTL), whose role is to kill microbe-infected cells thus inhibiting the spread
of the infection to un-infected cells [37]. The key to CD4+ and CD8+ T-lymphocyte
activation is their recognition of microbial antigens in association with Major
Histocompatibility Molecules via their antigen receptor, namely the T-cell receptor
(TCR). Major histocompatibility molecules are specialized proteins encoded by genes in
the Major Histocompatibility Complex (MHC) locus found on the chromosomes of all
vertebrates, whose role is to display peptide fragments (epitopes) of digested protein
antigens on the surface of body cells for recognition by T-lymphocytes. Class I MHC
molecules present epitopes for recognition by CD8+ T-cells, and are expressed on almost
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all nucleated body cells, while class II MHC molecules present epitopes for recognition
by CD4+ T-cells, and are only present on the surface of antigen presenting cells (APCs)
such as DCs, mononuclear phagocytes, and B-lymphocytes [36].
The only professional APCs that are capable of activating naïve T-cells and
initiating a primary CMI response are DCs, since they are the only APCs that possess the
co-stimulatory capacity required to activate those cells [38,39]. The two main types of
DCs isolated from peripheral blood are myeloid/conventional dendritic cells (mDC),
which originate from myeloid precursor cells, and plasmacytoid dendritic cells (pDC),
which originate from lymphoid precursor cells. mDCs and pDCs differ in their
capabilities of antigen presentation, expression of co-stimulatory molecules, and cytokine
production. mDC are much more efficient than pDC at antigen capture, processing, and
presentation. In the periphery, immature DCs (iDCs) are efficiently capable of capturing
exogenous antigens via the cell-internalization processes of receptor-mediated
endocytosis, macropinocytosis, and phagocytosis [38,39]. In the case of HCV, immature
DCs capture HCV antigens via phagocytosis of apoptotic infected hepatocytes,
endocytosis of HCV-immune complexes, and/or macropinocytosis of free virions [40].
Following antigen capture, DCs begin their maturation process triggered by microbial
products and inflammatory cytokines, and immigrate towards the secondary lymphoid
organs for the activation of antigen-specific naïve T helper and cytotoxic cells. DCs are
capable of presenting both MHC class II and class I antigenic epitopes via the exogenous
antigen processing pathway and cross-presentation respectively [38]. Figure 5
schematically represents the maturation process of iDCs into mDCs following HCV
capture, and the subsequent activation of T lymphocytes.
In chronic HCV infection, studies show that the numbers of DCs (both pDC and
mDC) in peripheral blood decrease and significantly increase in the liver; with the ratio
of mDCs to pDCs higher than that of peripheral blood [39]. Several studies also pointed
out that despite their distribution during chronic infection, DCs are functionally impaired.
mDCs have been reported to exhibit impaired maturation, decreased IL-12 production,
increased IL-10 production, lower ability to stimulate allogenic CD4+ T-cells, and higher
ability to stimulate T-regulator (Treg) cells; thereby, like NK cells, they produce an
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immunosuppressive environment that encourages viral persistence [39,41]. However,
other studies produced conflicting evidence showing that DCs in chronic HCV infection
are not functionally impaired. This contradiction in results is due to several factors such
as the limited number of study subjects, differences in host-related factors (e.g. age,
gender), source tissue of the analyzed DCs, and others; confirmation of either claim
requires further investigations to be carried out [13,39].
Upon reaching the peripheral lymphoid organs, mature DCs expressing the B7 costimulatory molecules present the captured and processed HCV antigens to naïve CD8 +
and CD4+ T-cells on MHC class I and class II molecules respectively. The recognition of
those antigens, in addition to co-stimulation by the B7 molecules and stimulation by
activator cytokines produced by the DCs, lead to the activation of circulating antigenspecific T-cells. Consequently, the activated T-cells proliferate and differentiate into
effector and memory cell subsets [42]. Activated CD4+ T-helper cells differentiate into
the IFN-γ secreting TH1 effector subset, induced by the cytokines IL-12 and IFN- γ found
in the immediate cytokine milieu. Activated CD8+ T-cytotoxic cells differentiate into
CTL effector cells which harbor membrane-bound cytoplasmic granules carrying proteins
required for killing infected cells, including perforins and granzymes, and are able to
produce certain cytokines including IFN- γ. It is important to note that in addition to the
activator signals provided by the mature DCs, CD8+ T-cells also require stimulation by
cytokines from TH1 helper cells to successfully differentiate into CTL effector cells
[31,42]. Following differentiation, part of the effector and memory T-cells migrate to the
liver, where they are preferentially retained. In the liver, CTLs that recognize their
specific antigen in association with MHC class I molecules on the surface of infected
hepatocytes become activated and kill the infected cells by inducing apoptosis.
Furthermore, CTLs secrete IFN-γ similar to the effector TH1 cells, which apart from
“helping” the differentiation of CD8+ T-cells into CTLs, stimulates the production of
opsonizing IgG antibodies from B-cells and the microbicidal activity of phagocytes [31].
The evolution of the T-cell response in HCV infected patients can be divided into
three phases in correlation with the progression of liver inflammation; namely the preacute, acute, and post-acute phases. The pre-acute phase corresponds to the first few
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weeks following the onset of primary infection where the virus titers rise to very high
levels and T-cell responses are still undetectable [43]. The acute phase starts 4-12 weeks
after primary infection onset when HCV-specific CD4+ and CD8+ T-cells become
detectable in blood. Concurrent with the rise in effector HCV-specific T-cell titers, HCV
RNA levels start to fall, often becoming transiently undetectable, and a rise in liver
enzyme titers may be experienced characterizing the development of acute hepatitis.
Early in the acute phase, when the viral load is still relatively high, activated HCVspecific CD8+ T-cells demonstrate a unique behavior where they do not secrete IFN-γ and
are defective in their cyototoxic activity despite their expression of activation markers.
This phenotype has been described by some investigators as a “stunned” phenotype,
where the CD8+ T-cells act as if they were anergic, and is considered a hallmark of acute
HCV infection regardless of its outcome. In patients who resolve the infection, HCVspecific CD8+ T-cell functionality is later restored concurrent with a significant drop in
HCV viral titers [43,44].
The T-cell response to HCV is known to peak on average 6-12 months following
infection onset; and it is the nature of that response in the acute phase which determines
the subsequent infection outcome, or to say the characteristics of the post-acute phase of
the infection [43]. Studies show that patients who spontaneously resolve the infection
exhibit a strong T-cell response targeting several viral epitopes. In these individuals, the
post-acute phase is characterized by the absence of HCV RNA from peripheral blood and
the persistence of stable long-lasting CD8+ and CD4+ memory T-cell pools after the
normal decrease in effector T-cell levels following HCV eradication. On the other hand,
patients in whom the disease progresses to a chronic phase exhibit a weak, narrow
(targeting very few epitopes), and short-lasting T-cell response to the virus. In these
individuals, the post-acute (chronic) phase is characterized by persistence of HCV RNA
in the blood, along with a permanent, almost complete loss of HCV-specific CD4+ Tcells and a dramatic decline in HCV-specific CD8+ T-cells which become persistently
functionally defective. The almost complete absence of CD4+ cells is critical for viral
persistence, and may also be responsible for the impaired CD8+ T-cells’ function [43,44].
Here it is important to note that the strength of the CD4+ T-cell response in acute
infection alone is not an accurate predictor of infection outcome, as studies showed that
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some individuals who managed to mount a strong CD4+ T-cell response against HCV
still developed chronic infection following an unexplained loss of that strong response
[43]. A graphical depiction of the 3 phases of the T-cell response to HCV and their
possible outcomes are illustrated in figure 6.
2.2.1.5 Adaptive Immunity – Humoral Response
The second arm of the adaptive immune response against HCV is the humoral
immune response, the effector response of B-lymphocytes against extracellular microbes
and microbial toxins mediated by neutralizing antibodies secreted from those cells [31].
Unlike CMI where T-cells can only recognize linear epitopes, B-cells can recognize both
linear and conformational epitopes on their target antigens via their membrane-bound
antibody receptors. Anti-HCV antibodies become detectable in the patients’ blood around
4-14 weeks post-infection [15]. The natural targets of these antibodies are epitopes of the
structural E2 and E1 HCV envelope proteins; however, anti-HCV antibodies targeting
epitopes of non-structural HCV proteins or their incomplete degradation products
released from dying hepatocytes are also detected [15,45]. By binding to the E1 and E2
proteins, anti-HCV neutralizing antibodies would block the entry of HCV into uninfected
hepatocytes, and facilitate the capture of HCV by macrophages (opsonization) [43]. The
antibodies can be either isolate-specific, targeting epitopes only found in the viral strain
infecting the patient, or cross-neutralizing, targeting epitopes found in several strains,
possibly providing cross-genotype protection [15].
In addition to antigen recognition, the activation of protein antigen-specific naïve
B-cells in peripheral lymphoid organs requires help from effector CD4 + T-helper
lymphocytes. Upon binding their antigen, naïve B-cells internalize the antigen-antibody
receptor complex, process the internalized protein antigen, and present its epitopes on
MHC class II molecules for CD4+ T-cell recognition. When antigen-specific effector Thelper cells recognize the presented antigen, they send activatory signals to the antigenpresenting B-cell in the form of cytokines and CD40-Receptor to CD40-Ligand
(CD40:CD40L) interactions; these signals stimulate B-cell proliferation, differentiation
into antibody-secreting plasma cells, and antibody heavy chain isotype switching.
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Furthermore, CD4+ T-cell help is also required for antibody affinity maturation and
differentiation of some of the activated B-cells into memory cells [42]. In HCV infection,
the activated TH1 CD4+ effector cells play the aforementioned helper role. The IFN-γ
secreted by those cells stimulates antibody isotype switching to Immunglobulin G (IgG)
antibodies, which, upon binding to the structural viral proteins, block viral entry into the
hepatocytes and promote phagocytosis by macrophages [31].

2.2.2 Viral Evasion Mechanisms from the Immune Response:
In order to persist, HCV has developed several mechanisms by which it can evade
both arms of the host immune response [13]. First, HCV counteracts the innate immune
response by interfering with type I IFN production and function and inciting NK and DC
cell dysfunction [13,14]. Later when the adaptive immune response develops, HCV owes
its survival mainly to the highly mutable nature of its genome, driven by its RNAdependant RNA polymerase, NS5B, which lacks proofreading capability. Furthermore,
HCV counteracts the effector functions of the cellular immune response by causing the
exhaustion of T-effector cells and by inducing the activation of regulatory T-cells. It also
evades the neutralizing actions of anti-HCV antibodies by physically shielding the target
epitopes of those antibodies by several mechanisms that will be explained in this section
[13,15].
When HCV structural and non-structural proteins are synthesized, they interfere
with type I IFN production and function by interacting with key components of the signal
transduction pathways leading to type I IFN and ISG expression, and later with the
products of the ISG genes themselves [14,29,30]. The NS3/4A viral protease and the NS3
protein interfere with the expression of IFN-β, where NS3/4A cleaves the adapter
proteins MAVS (mitochondrial antiviral signaling protein, also known as VISA, Cardif,
and IPS-1) and TRIF (TIR domain-containing adaptor-inducing IFN-β) that are essential
components of the RIG-I and TLR3 signaling pathways respectively, and where NS3
interacts with TBK-1 (TANK binding kinase 1) which is a component of the RIG-I
signaling pathway, leading to a decrease in IFN-β expression as they accumulate in the
cells [14,30]. The structural Core protein and NS5A later interfere with the expression of
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ISGs by inhibiting the activation of the Signal Transducer and Activator of Transcription1 (STAT-1) protein of the JAK/STAT pathway that leads to the induction of ISG
expression. The Core protein was also shown to inhibit the binding of the ISG factor 3
(ISGF3) transcription factor to the IFN-stimulated response element (ISRE), induce the
expression of the JAK/STAT pathway inhibitor “Suppressor of Cytokine Signaling 3”
(SOCS3), and induce the upregulation of protein phosphatase 2 (PP2A), which then
indirectly attenuates the transcriptional activity of ISGF3 [14,29,30].
In addition to interfering with the signal transduction pathways leading to IFN and
ISG expression, the HCV proteins NS5A and E2 interfere with the products of the ISG
genes themselves. Studies reported that the NS5A and E2 proteins of HCV genotype 1
strains both interact with and inhibit Protein Kinase R (PKR), which originally reduces
protein synthesis in the cell and concurrently inhibits viral replication [14,29,30]. These
effects on PKR function however have to be validated since reports on them vary
depending on the HCV isolate and experimental setting, and furthermore, they were not
consistent in the reports of different research groups [29]. In addition to its interaction
with PKR, NS5A was also reported to inhibit 2’–5’ oligoadenylate synthetase (OAS) and
induce the expression of IL-8; which inhibits overall ISG expression [14,29]. Figure 7
demonstrates the interaction of the aforementioned HCV proteins with the different
components of the signaling pathways leading to IFN and ISG expression and with the
products of the ISGs.
In addition to counteracting type I IFN production and function, as
aforementioned, HCV persistence culminates in NK and DC cell dysfunction observed in
the chronic phase of the infection. Both NK and DC cells start to release cytokines that
produce an immunosuppressive environment where the CD4+ TH1 cell response is
weakened; encouraging viral persistence. Till now, the underlying molecular mechanisms
causing NK and DC cell dysfunction have not been fully elucidated. With regard to NK
cell dysfunction, a study conducted by Nattermann et al. in 2005 concluded that an
epitope from the HCV core protein is responsible for the stabilization of expression of the
non-classical HLA class I molecule HLA-E which engages the inhibitory receptor
NKG2A; this interaction inhibits NK cell-mediated cytotoxicity [41,46]. Another study
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conducted by Herzer. et al in 2003 suggests that the core protein is also responsible for
the up-regulation of classical MHC class I expression on the surface of the infected cells
via the p-53 dependant up-regulation of the transporter associated with antigen
processing 1 (TAP1) protein, which consequently increases MHC class I expression. This
enhanced expression leads to the inhibition of NK cell mediated killing of the infected
hepatocytes [41,47]. With regard to DC cell dysfunction, studies show that the core, NS3,
NS4, and NS5 HCV proteins are implicated in down-regulating the expression of HLA
and costimulatory molecules, the reduction of cytokine production, and diminishing the
DCs’ allostimulatory activity [39].
Prior to the development of the adaptive immune response, several genetic
variants (quasi-species) of HCV develop and accumulate driven by the faulty replication
process of HCV RNA that is catalyzed by the error-prone viral NS5B polymerase
[44,48]. When the adaptive immune response develops, selective immune pressure is
exerted on the existing viral variants and a significant decline in viral blood titers is
recorded. At this point, only those variants whose epitopes cannot be recognized by the
effector cells of the adaptive immune system persist, and the ensuing mutation patterns of
HCV become directed at altering those epitopes that are amenable to immune
recognition. This is achieved by mutating the amino acid residues within those epitopes
that interact with and are recognized by the T-cell receptors and B-cell receptors of
effector T-cells and B-effector cells respectively, by mutating the amino acid residues
responsible for anchoring T-cell epitopes in the host’s HLA molecules, and/or by altering
the proteosomal cleavage sites of the viral proteins thereby interfering with T-cell epitope
processing and presentation [44,48]. The mutability of those epitopes, however, is
restricted by the “fitness cost” those mutations will have on the virus; where the mutation
of epitopes located within functional proteins (e.g. NS3, NS5B) will have a higher fitness
cost than mutating epitopes located within structural proteins (e.g. E1, E2) as those
“functional” epitopes could contain key amino acid residues for the functionality of the
proteins they are located within. Targeting such functional epitopes gives the host an
advantage and increases the chances of clearing the virus as those epitopes are harder to
mutate [44,48].
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Besides the mutational escape from recognition by HCV-specific T-effector cells,
HCV counteracts the cellular immune response against it by causing T-effector cell
exhaustion; which is defined as the gradual loss of T-effector cell functions due to the
prolonged exposure to high levels of its cognate antigen [14,41,49]. This might occur due
to a high viral replication rate exceeding the capacity of containment by the host’s
immune system [13,49]. One of the major causes of the induction of T-cell exhaustion in
T-effector cells is the high and/or prolonged expression of inhibitory receptors; and one
of the major receptors involved is the Programmed Death-1 receptor (PD-1) [49]. Studies
show that PD-1 expression is upregulated on HCV-specific effector CD8+ T-cells in
chronic HCV infection as a result of prolonged antigenic stimulation. The PD-1 receptor
on these cells interacts with its ligand PD-Ligand 1 (PD-L1) which is expressed on
infected hepatocytes preferentially, Kupffer cells, stellate cells, and sinusoidal endothelial
cells in the liver. This interaction initiates a signaling pathway that culminates in the
inhibition of the T-cell effector functions and eventually causes apoptosis [14,50]. The
gradual loss of T-cell effector functions starts by the loss of IL-2 (an important T-cell
growth factor) secreting activity, followed by the loss of TNF-α secreting activity and
CD8+ T-cell cytotoxicity, then finally by a substantial decrease in IFN-γ secreting activity
[14,41]. The lack of help from CD4+ T-cells aggravates the severity of CD8+ T-cell
exhaustion [14,49]. This correlates with the aforementioned picture of the blood of
chronically infected Hepatitis C patients, where there is a permanent, almost complete
loss of HCV-specific CD4+ T-cells and a dramatic decline in HCV-specific CD8+ T-cells
that become persistently functionally defective.
Another mechanism by which HCV counteracts the cellular immune response is
the induction of T-regulatory cells [39,51]. T-regulatory cells are characterized by the
expression of the transcription factor forkhead box P3 (FOXP3), the constitutive
expression of the IL-2 receptor α-chain (CD25), and the cluster of differentiation-4
(CD4), and their actions are one of the major mechanisms by which the body maintains
immune homeostasis, moderates inflammation, and prevents autoimmune reactions in the
periphery. There are two kinds of T-regulatory (Treg) cells: natural (n) Treg cells that are
selectively produced in the thymus as a consequence of their TCRs’ high affinity towards
self antigens, and induced (i) Treg cells that are derived from conventional CD4 + T20

effector cells converted in the periphery via induction by nTreg cells. This conversion is
induced either directly through cytokine-dependant mechanisms (IL-35, IL-10 or TGF-β)
or indirectly through DC-mediated mechanisms [39,51]. Like CD4+ T-helper cells, Treg
cells are activated in an antigen-specific manner; which happens when their TCR
recognizes its cognate epitope in association with MHC class II molecules [52]. When
they are activated, they suppress the actions of several types of immune cells including
effector T-cells and B-cells, NK cells, DCs, and macrophages via several mechanisms;
these include: (1) suppression via inhibitory cytokines (IL-35, IL-10 or TGF-β), (2)
suppression of T-effector cells by metabolic disruption, such as triggering apoptosis by
IL-2 deprivation driven by the high expression of the IL-2 receptor on the Treg surface,
(3) triggering apoptosis of T-effector cells via granzymes A and B and perforin, and (4)
inhibiting DC maturation and ability to stimulate naïve T-cells [39,51]. A schematic
representation of the suppressive mechanisms of Tregs is illustrated in figure 8.
In HCV infection, studies have shown that the number of Treg cells (both
nTregs and iTregs) in the liver and peripheral blood of chronically infected patients is
higher compared to uninfected individuals or those who have spontaneously cleared the
virus [13,39]. In vitro studies showed that the depletion of CD25+ cells (where CD25 is
another marker expressed by Tregs) from chronic HCV patient blood samples resulted in
the enhancement of HCV-specific T-effector cell responsiveness[13,14]. While it was
unclear whether this increased Treg activity is a byproduct of chronic inflammation and
liver disease or the direct induction by T-regulatory cell epitopes, further investigations
have uncovered the presence of Treg epitopes (Tregitopes) within HCV structural and
non-structural proteins, presenting supporting evidence for the specific induction
hypothesis. It was also found that some of these epitopes exhibit strong homology with
human self antigens, thus explaining the response and expansion of nTreg cells which are
normally involved in the suppression of autoimmunity upon encountering self epitopes
[39]. Furthermore, a recent study by Cusick et al demonstrated that, within the course of
chronic infection, an immunodominant HCV MHC class II epitope was mutated into a
Tregitope under the host’s immune pressure [39,53]. These studies elaborate the
prominent role of Treg cells in the promotion of chronicity development.
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In addition to the mutational escape from recognition by neutralizing anti-HCV
antibodies, HCV evades the humoral immune response by several other mechanisms
[15,54]. First, HCV can induce the production of non-neutralizing antibodies that
interfere with the binding of neutralizing anti-HCV antibodies to their target epitopes.
Studies proposed that a group of epitopes located between amino acids 434-446 in the E2
protein region, collectively called “epitope II”, trigger the production of non-neutralizing
antibodies whose binding to their target epitopes blocks the actions of neutralizing
antibodies that target another adjacent E2 protein region between amino acids 412-426
called “epitope I” [15,45,54]. Second, HCV can escape the action of neutralizing
antibodies by binding to lipoproteins while circulating in blood, as it has been
aforementioned; this association masks the HCV epitopes targeted by those antibodies
[12,15,54]. Third, the interaction between the hypervariable region 1 (HVR1) -a highly
variable region within the E2 protein-, high density lipoproteins (HDL), and the
Scavenger Receptor class B type I (SR-BI) provides protection against neutralizing
antibodies targeting epitopes outside HVR1. Studies on HCV pseudo-particles (HCVpp)
have shown that the deletion or mutation of HVR1, the removal of HDL particles, or the
abolishment of the SR-BI lipid transfer activity obliterates the resistance to antibodymediated neutralization [15,54]. Fourth, HCV can shield the target epitopes of
neutralizing antibodies on the envelope glycoproteins (E1 and E2) by N-glycosylation.
Studies on HCVpp show that removing glycans from these proteins increases the
susceptibility of neutralization of HCVpp by anti-HCV antibodies [15,54,55]. Finally,
HCV can evade recognition by neutralizing anti-bodies by infecting neighboring cells via
direct cell-to-cell transfer rather than via the receptor-mediated uptake of HCV particles
released from the infected cells into its surroundings [15,54]. The aforementioned
mechanisms are illustrated schematically in figure 9. An overall summary of the immune
response to HCV and the mechanism by which it evades that response is schematically
represented in figure 10.
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2.3

HCV Vaccine Development

2.3.1 Characteristics of an ideal HCV vaccine:
In light of the knowledge we have so far on the immune response to HCV, it can
be inferred that an ideal HCV vaccine would target highly conserved regions in the HCV
genome. Targeting such regions which are mainly conserved for their important structural
and functional roles in the HCV life cycle would increase the chances of establishing
protection against several HCV strains, as it is less likely for the virus to mutate those
regions in order to evade recognition at low fitness costs. An ideal HCV vaccine would
also be able to elicit a sustained immune response, one which would successfully create a
sustained pool of memory cells that can act upon future encounters with the virus. It
would also be capable of triggering a multi-specific response, as studies have shown that
targeting several conserved viral epitopes is associated with viral clearance as the virus
has a further lower chance of immune evasion via mutating several conserved epitopes at
the same time. Furthermore, an ideal HCV vaccine should be safe and not trigger any
immunopathology; a goal that has proven to be realistic in the light of previous human
studies [17].

2.3.2 Challenges facing HCV vaccine development:
The process of HCV vaccine design and development was hindered by several
challenges; some of which have recently been overcome. The first of these challenges
was to design a vaccine that would overcome the mechanisms by which the virus evades
the host’s immune response, foremost the highly mutable nature of the virus. The high
mutation rate of the HCV genome makes the development of a cross-genotype effective
vaccine very difficult; and for this reason, the development of a prophylactic antibodyinducing vaccine that targets the E1 and E2 envelope proteins, which are the obvious
targets for such a vaccine, has been a big challenge, owing to the hyper-variable nature of
the major antigenic determinants of those proteins [17].
The second challenge that faced vaccine development was overcoming certain
practical obstacles; one of these obstacles was the inability to produce HCV particles in
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vitro, which made it difficult to understand several aspects of the virus’s life cycle and
mechanisms of interaction with its host. The first solution to this problem was put forth in
2003 when HCV pseudo-particles (HCVpp) were developed, which are retroviral and
lentiviral core particles pseudo-typed with the E1 and E2 structural viral proteins of
HCV. The study conducted using these particles provided insight on HCV’s entry
mechanisms into hepatocytes and the antibody-mediated neutralization of HCV particles
through targeting E1 and E2 epitopes [17,56]. After that in 2005, the first successful
infection tissue model for HCV was developed, where a unique variant of HCV was
cultured in human hepatoma cell line Huh-7 cells. This provided further insight into the
stages of the HCV life cycle in the host’s hepatocytes [17,18]. Another practical obstacle
that HCV vaccine development faced was that the only animal model available as a
model for infection and for pre-clinical testing of vaccine candidates was the chimpanzee.
Although proven useful due to the similarity of its immune response mechanisms to
humans, the chimpanzee animal model has its financial, practical, and sometimes ethical
limitations which, in previous studies, allowed only the use of small numbers of this
model weakening conclusions that could be drawn from those studies’ results. This
problem has been dealt with by the development and utilization of transgenic humanized
mouse models; these include models expressing human HLA class I molecules used for
HCV epitope analysis, and others expressing HCV entry receptors on their hepatocytes
which allow for the acceleration of the screening process for potential vaccine candidates
[17,19].
Another practical obstacle, particularly facing prophylactic vaccine development,
is the challenge of designing a clinical trial for testing the efficacy of a candidate
prophylactic vaccine. In developed countries, the low incidence of HCV infection limits
the availability of test subjects, except if the study was designed to target intra-venous
drug users; targeting this test group in the study raises additional practical and ethical
obstacles on its own. In developing countries where the incidence of HCV is higher,
careful follow up of the test subjects must be ensured owing to the asymptomatic nature
of acute infection. Furthermore, since the vaccine in theory may require some time to
facilitate the clearance of the virus, the timing of the start of IFN therapy must be
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carefully considered; given the delayed efficacy of the vaccine, the optimal time of
commencing therapy may be well after that recommended by current guidelines [17].

2.3.3 HCV vaccines in clinical trials:
Despite the challenges that faced and still face HCV vaccine development, several
vaccine studies conducted over the past decade on animal models have yielded promising
results; a few of these studies have put forth vaccine candidates that have actually entered
human clinical testing [17,19]. Most of these studies focused on the evaluation and
development of therapeutic vaccine candidates, which aim at preventing/alleviating the
complications associated with disease progression and assisting in the eradication of the
virus in combination with standard therapy. A smaller number of those studies have
focused on the evaluation and development of prophylactic vaccines, which aim at
immunizing the host to prevent infection. With regard to pre-clinical testing (i.e. in
animal models), most studies showed that the developed vaccine candidates were indeed
able to elicit HCV specific immune responses, which were able to alter the course of
subsequent challenge infections by allowing better control over viral replication and
increasing the likelihood of clearing the virus [17,57]. HCV vaccine candidates currently
undergoing clinical trials are extensively reviewed in Halliday et al. 2011 [17]. Examples
of those vaccines and the results of their clinical testing are listed in table 2.

2.4

Computational Vaccinology and Epitope-driven vaccine design
In conjunction with the ever increasing applications of bioinformatics in

biotechnology, immunoinformatics, the branch of bioinformatics concerned with
immunology and vaccinology, has allowed researchers to uncover important functional
information impacting molecular immunology; furthermore, it has opened the door for
the revolutionary field of Computational Vaccinology [58]. Computational vaccinology
refers to the computer-aided design of vaccines, where immunoinformatics and
bioinformatics tools are used to identify potential vaccine targets within a target genome
in silico before being empirically tested and validated [59]. There are generally two
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approaches for vaccine design computationally, the first being the antigen-driven
approach, where the target genome is screened with the aim of identifying protective
antigens; for example, a pathogen’s genome can be screened for sequence patterns
characteristic of cell surface-expressed proteins that can potentially induce humoral
immunity. The second approach is the epitope-driven one, where the target genome is
scanned with the aim of identifying immunogenic T-cell and B-cell epitopes; these
epitopes are then either themselves synthesized in an appropriate form and packaged in
an appropriate delivery vehicle to be used as a vaccine (e.g. peptide vaccine or DNA
vaccine), or can be used to identify potentially protective whole protein antigens from the
target genome which can be used as vaccine targets (referred to as “fishing for antigens
using epitopes as bait”) [60]. The total repertoire of protective epitopes (T-cell and Bcell) derived from a target genome/proteome is referred to as the Immunome [60].
Over the past decade, the process of epitope-driven vaccine design (also known
as Immunome-Derived vaccine (IDV) design) has witnessed several applications in
cancer and infectious disease vaccine development, bolstered by the availability of a wide
variety of specialized immunoinformatic epitope-mapping (immunome-mining) tools,
which are designed for the in silico identification of T-cell and B-cell epitopes from the
target genome/proteome [23,60]. There is a wide variety of efficient algorithms
developed for T-cell epitope mapping which have found application in several research
laboratories in the field of drug discovery; however, fewer algorithms have been
developed for B-cell epitope mapping which are not very efficient at epitope prediction.
This is due to the nature of B-cell and T-cell epitopes, where the linear and shorter form
of T-cell epitopes makes it simpler to develop algorithms for their prediction compared to
B-cell epitopes which may be conformational in nature [59-61].

2.4.1 Advantages of immunoinformatics-guided epitope-driven vaccine design:
In comparison to traditional vaccines, IDVs possess the potential of being safer
and more effective [23]. The higher potential effectiveness of IDVs is due to the fact that
the vaccine is designed to focus the immune response on the most immunogenic and
essential epitopes of the target pathogen or neoplasm. With regard to safety, IDVs are
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considered safer than live attenuated and vector vaccines; furthermore, since IDVs can be
designed in a minimalist form to contain only the target epitopes rather than whole
protein antigens, they may be able to avoid some of the health hazards associated with
some of those antigens. For example, despite its high cross-genotype conservancy, it was
found that the Core protein of HCV is able to induce hepatocellular carcinoma in
transgenic mice and cause steatosis formation [25]. Accordingly, the use of immunogenic
epitopes from the core rather than the core antigen itself in a vaccine would be considered
safer.
Compared to the traditional empirical method where scientists used to isolate
target proteins (antigens) and process them to extract and test all potentially
immunogenic epitopes [60], epitope-mapping tools allow for the in silico identification of
the most immunogenic of those epitopes before further testing is carried out in the wet
lab. This saves the time and costs associated with testing all potentially immunogenic
epitopes empirically before selecting the most immunogenic ones that can actually be
included in a vaccine. Furthermore, while the empirical method may result in some
important epitopes being overlooked due to imprecise protein digestion, epitope-mapping
tools may avoid that if an efficient algorithm is used to scrutinize all possible “epitope
frames” within a target protein sequence [58,61]. In addition to being able to map
epitopes in silico, immunoinformatcs/bioinformatics tools also allow for homology
testing of those epitopes against the human genome with the aim of avoiding the use of
epitopes that have homologous sequences in the human genome. If used, such epitopes
may trigger a suppressive immune reaction due to the immune system being tolerant to
them, or may trigger an autoimmune reaction against self. Accordingly, avoiding the use
of such epitopes potentially also makes the vaccine safer and more effective [23,60].

2.4.2 Types of T-cell epitope-mapping tools:
In the past, T-cell epitope mapping algorithms were designed to predict T-cell
epitopes directly, based on the hypothesis that T-cell epitopes are amphipathic structures
with a hydrophilic side facing the T-cell receptor (TCR) of T-cells, and a hydrophobic
side facing the binding groove of the MHC molecule; such algorithms were referred to as
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“direct” methods of epitope prediction [58]. Currently utilized T-cell epitope mapping
algorithms however are those designed to predict T-cell epitopes based on the binding
specificities of the MHC molecules rather than the molecular structures of the epitopes
themselves; such methods are referred to as the “indirect” methods of prediction, and can
be classified according to their prediction approaches into: motif-based methods, matrixbased methods, machine-learning-based methods, and ab intio methods [58].
In motif-based methods, epitope prediction algorithms predict MHC binders by
screening for specific amino acid residues, called “anchor” residues, in the target peptide
sequence [58,62]. Anchor amino acid residues of T-cell epitopes interact with
polymorphic amino acid residues in MHC molecules which are located within certain
‘pockets’ in the MHC epitope-binding region (explained in detail in the next section);
these polymorphic residues differ from one MHC molecule to the other, and
consequently the nature of the anchor residues of the T-cell epitopes they bind. The
recurrent pattern of anchor residues that bind each MHC molecule is referred to as a
“motif” [62]. Although proven valuable, the in vitro validation of the in silico results
generated by these methods showed that they are relatively nonspecific, as they predicted
epitopes that did not bind to their respective MHC alleles or were not immunogenic, and
insensitive, as they failed to predict true binders that did not bear the anchor residues
however bore 2ry anchor non-conserved residues at other locations in the peptides
[58,62]. Specificity of a prediction algorithm is a measure of its efficiency in excluding
non-binder epitopes, while sensitivity is a measure of its efficiency in including true
binders in its predictions [62].
In contrast to the motif-based approaches which assume that only anchor amino
acid residues contribute to epitope binding, matrix-based approaches on the other hand
account for the contributions of all amino acids of a target epitope in their predictions
[62]. When constructing a matrix-based epitope prediction tool, a reliable training set of
epitope-binding data is first identified. Then quantitative or frequency matricies for each
MHC molecule to be included in the predictions are constructed by analyzing the
distribution of amino acid frequencies at each position in the binding cleft of the MHC
molecule and/or the influence of each amino acid binding at each position on the overall
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binding affinity of the epitope, and then using the outcome of the analysis to assign a
numerical value for every one of those amino acids at their respective binding positions.
The prediction of the binding affinity of new epitopes is then carried out by looking up
the values assigned for each amino acid in the epitope relative to its position in the MHC
molecule in the matrix, and then either adding or multiplying these values to obtain an
overall score for the peptide that is used to predict its likelihood of binding relative to a
predetermined cut-off value [62,63]. Matrix-based approaches perform better compared
to motif-based approaches; however, they handle data in a ‘linear’ manner, where they
consider the individual contributions of each amino acid residue in the epitope to epitope
binding independently; this is not the case in reality, as epitope binding is not determined
by the simple summation of the contributions of each amino acid residue at each position
in the target epitope [58].
While matrix-based prediction approaches cannot handle non-linearity in data,
machine learning based approaches can. A limitation of such approaches is, however, that
they require a relatively large MHC binder training dataset for their construction, which
is available for a small, albeit increasing, number of MHC molecules/alleles. There are
several examples of machine-learning techniques employed in T-cell epitope prediction
algorithms such as artificial neural networks (ANN), Hidden Markov Models (HMM),
and Support Vector Machines (SVM) [58]. The last approach for T-cell epitope
prediction is the ab initio approach, which functions by predicting binders to an MHC
molecule using a structural model of that molecule without the requirement for a training
dataset. This approach however requires an elucidated 3D structural model of the MHC
molecule of interest as well as high computational power for performing the analysis
[58].

2.5

The Human Leukocyte Antigen
As aforementioned, the Major Histocompatibility Complex (MHC) molecules are

specialized proteins encoded by genes in the Major Histocompatibility Complex locus
found in the chromosomes of all vertebrates, their role is to display peptide fragments
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(epitopes) of digested protein antigens on cell surfaces to be recognized by Tlymphocytes leading to their activation; class I MHC molecules are expressed on all
nucleated cells and activate CD8+ T-cytotoxic lymphocytes, while class II MHC
molecules are only expressed in antigen presenting cells and activate CD4 + Tlymphocytes. In humans, the major histocompatibility complex is also known as the
Human Leukocyte Antigen (HLA), and is present on the short arm of chromosome 6
[36,64].

2.5.1 HLA molecules:
HLA molecules are glycosylated heterodimeric transmembrane proteins
composed of two non-covalently associated polypeptide chains; in HLA class II
molecules, both polypeptide chains are encoded by HLA class II genes and are called
chains α and β, while in HLA class I molecules only one of the chains is encoded by
HLA class I genes, called the heavy α chain, while the other chain in not encoded by the
HLA locus and called the light β2-microglobin chain [36,64].

The overall tertiary

structure of HLA molecules can be divided into four parts: an extracellular N-terminal
peptide (epitope)-binding region, an extracellular Immuno-globulin (Ig)-like region, a
hydrophobic transmembrane region, and finally a small C-terminal cytoplasmic region.
The epitope binding region is composed of two α-helices resting on an eight-stranded βpleated sheet forming a cleft within which epitopes bind for presentation to Tlymphocytes in a linear conformation. In HLA class II molecules, the binding cleft is
composed of the N-terminal domains of the α and β chains called α1 and β1 respectively,
where each domain is formed of about 90 amino acids and contributes to half of the
structure; the ends of the binding cleft are open, which is why HLA class II epitopes tend
to have a variable length that can reach 30 amino acids, typically however falling within
the range of 13 to 25 amino acids. In HLA class I molecules on the other hand, the
binding cleft is composed of two N-terminal domains of the α chain called α1 and α2; in
contrast to class II molecules, the ends of the binding-cleft are closed, restricting the size
of HLA class I epitopes to 8-11 amino acids[36,64]. A third domain of the α chain, called
α3, forms the Ig-like extracellular region; and is responsible for interacting with the CD8
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molecule of the T-cytotoxic lymphocytes. In class II molecules, the same function is
performed by the β2 region of the β chain, which forms the Ig-like domain that interacts
with the CD4 molecule of T-helper lymphocytes [36,64].
With regard to HLA class II epitopes, the affinity and specificity with which they
bind to the epitope-binding cleft of the HLA class II molecule is mainly determined by a
core region in those epitopes made up of 9 amino acids [65]; the remaining AA residues
flanking the core region also assist in peptide binding by enhancing the binding affinity
and stability of the molecular complex [66]. The peptide backbone of the core region
interacts with conserved residues in the MHC binding-site via hydrogen bonds, which
maintains the peptide in a linear conformation with the core region of the peptide having
a conserved secondary structure resembling that of a polyproline chain [64,67]. In this
conformation, side chains of AA residues 1, 4, 6, and 9 of the core region of the peptide
are directed ‘into’ the binding-cleft; where they interact with four major pockets
distinctive of the MHC class II binding-site. The properties of these pockets vary from
one MHC class II isotype (molecule) to the other, and determine the specificity with
which the epitopes bind to the binding-groove. Furthermore, the interaction of the stated
AA residues with the pockets enhances the stability of the molecular complex; which is
why these residues are called the ‘anchor’ residues of the peptide [65-67]. Side chains of
other AA residues in the core region of the peptide also interact with different AA
residues in the β-pleated sheet floor and α-helix walls of the binding groove via hydrogen
bonds and salt-bridges; interactions which also contribute to the binding affinity of the
peptide. For the peptide to be identified by its antigen-specific T-helper cell, side chains
of certain AA residues from the core region protrude upwards away from the binding
cleft to interact with and be recognized by the T-cell receptor (TCR) of the TH-cell. The
TCR, however, does not only interact with those residues, but it also interacts with
polymorphic AA residues of the α-helices of the MHC itself [36,64]. A 3D illustration of
an epitope associated with an HLA class II molecule binding cleft is presented in figure
11.
HLA class I epitopes are accommodated in the binding groove of HLA class I
molecules by anchoring the ends of the epitope and allowing its middle portion to bulge
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upwards. Amino acid side chains of anchor residues at the N and C termini of the
epitopes –usually the first and last two- are directed “downwards” into the binding cleft
where they interact with amino acid residues found within pockets in the HLA binding
cleft, similar to the case of the binding of HLA class II epitopes to their binding cleft.
Different HLA molecules encoded by different genes have different pockets, and hence
can bind to different peptides. Furthermore, different HLA molecules encoded by
different alleles of a given HLA class I gene also show minor differences in their
specificity towards anchor residues [64]. Typically, the main contribution to the binding
affinity of an epitope is provided by the residues at position 2 and at the C-terminus of
the peptide, which interact with 2 pockets in the binding cleft called “B” and “F”
respectively [68]. Amino acids in the middle of the epitope are directed upwards where
they interact with the TCR of T-cytotoxic lymphocytes; determining the specificity and
affinity with which the TCR binds to the HLA-peptide complex. These residues also
partly contribute to the peptide binding affinity to the HLA molecule. If it is
conformationally possible, HLA class I molecules can accommodate epitopes longer than
10 amino acids if their central amino acid residues can bugle upwards [64].

2.5.2 HLA genes:
The α and β chains of the HLA class II molecules are encoded by multiple
functional genes found in the MHC locus on chromosome 6; these genes are located
within three regions in this locus, namely DR, DQ, and DP. The DP region harbors genes
for two α and two β HLA chains; of which only α1 and β1 are functional. The same is
true for the DQ region; except that it includes a third non-functional gene for a β HLA
chain (β3). The DR region on the other hand is different; where it harbors only one gene
for an α HLA chain that is monomorphic in the region encoding for the peptide-binding
α1 domain of the α chain, and 9 polymorphic genes for HLA β chains. Of the nine, only
genes number 1, 3, 4, and 5 are functional. β chain genes numbers 1 and 9 are present in
all individuals, but the presence or absence of genes 2-8 in DR varies from one individual
to the other [36,64]. When translated, the α and β chains encoded by genes of the same
region (e.g. DR) most usually form the HLA molecule; and on rare occasions do the α
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and β chains encoded by genes of different regions (e.g. DR and DQ) form the molecule.
Mixing between α and β chains of the same region but encoded on genes from different
parental origin is also common. Both paternal and maternal chromosomes are codominantly expressed [36,64].
As for HLA class I molecules, the α chain is encoded by multiple functional genes
also found in the HLA locus on chromosome 6. In contrast to HLA class II however, the
β2-microglobin chain is encoded by an invariant gene on chromosome 15. The genes
encoding for the α chain are denoted HLA-A, B, and C. Just like HLA class II genes,
maternal and paternal HLA class I genes are co-dominantly expressed; which means that
for each individual there can be six variants of the HLA class I molecule expressed on all
nucleated body cells. However, the levels of expression of the different HLA class I
genes differ. For example, 20-50% of individuals depending on the race do not seem
express a functional HLA-C protein [36,64].

2.5.3 HLA classification and nomenclature:
In the past, the characterization of HLA variants was performed by serological
typing [69,70]. This lead to the classification of HLA molecules into serotypes, where a
serotype is defined as the HLA molecule(s) that are detected by an available respective
antibody. The serological typing method cannot, however, identify all existing HLA
genotypes individually. This is because the available HLA-specific antibodies are smaller
in number compared to the ever increasing number of HLA alleles, and are moreover
hard to detect. Furthermore, HLA antibodies cannot detect null HLA alleles which are
not expressed. As a result of that, each defined HLA serotype usually describes several
HLA allelic variants. Furthermore, some of the defined HLA serotypes describe “broad
antigens” as they are further sub-categorized into “split antigens” owing to the increase in
sensitivity and refinement of Serotyping methods over the years which lead to the
identification of new anti-HLA antibodies [71]. As a result of lower specificity, broad
antigen serotypes exhibit cross-reactivity with the split antigen serotypes; for example,
the HLA-A9 serotype describes a broad antigen whose antibody can detect HLA-A23 and
A24 split antigens [71,72].
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When HLA DNA typing methods were developed, such as the PCR-based
sequence specific oligonucleotide probing (PCR-SSOP), sequence-specific priming
(PCR-SSP), and sequencing-based typing (PCR-SBT) methods, a more specific
nomenclature system for the characterization of HLA genes and alleles was developed
[69,71,72]. Assigning names for new HLA genes and alleles is performed by the World
Health Organization’s (WHO) Nomenclature Committee for Factors of the HLA System
using a specific format [71]. Based on the latest update of the format of the nomenclature
system, HLA alleles are to be denoted by an “HLA” prefix, followed by the gene name,
followed by 4 fields of digits, and finally a one letter suffix, with all components
separated by specific separators which are: a hyphen between the HLA prefix and the
gene name, an asterix between the gene name and the digit fields, and finally colons
between the digit fields themselves (e.g. HLA-A*02:01:01:02N). The first two digits in
the digit fields are used to describe the allele family, which usually corresponds to the
serotype of the HLA. The third and fourth digits describe HLA alleles whose sequences
harbor non-synonymous mutations in the expressed protein sequence (exons), mainly in
the regions coding for the epitope-binding site of the molecule, and are assigned based on
the order by which the sequences of the alleles have been elucidated. Synonymous
mutations that occur in the exons are described by the fifth and sixth digits of the name.
The seventh and eighth digits are used to describe mutations in the introns or the 5’ and
3’ untranslated regions of the alleles. Finally, the one letter suffix is used to describe the
expression status of the allele (e.g. “N” refers to “null allele”, while “L” refers to “Low
expression level”) [73,74]. Depending on the DNA typing method utilized, the resolution
of HLA typing can vary between low resolution typing, which characterizes the allele
with respect to the allele family only (first digits field), to high resolution typing, which
characterizes individual alleles based on the amino acid sequences of the their epitopebinding sites (first two digit fields), to “allelic” resolution, which characterizes the full
DNA sequence of the typed allele [73].
In addition to the serological and genetic nomenclature systems, HLA variants
can be also classified based on the structural features of the epitopes they bind. X-ray
crystallographic analysis of the epitope-binding regions of HLA molecules have shown
that their polymorphic residues are located within ‘pockets’ in the cleft and are
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responsible for determining the binding specificity of the HLA molecule by engaging
certain anchor residues in their target epitopes. Analysis of the amino-acid sequences of
the epitope repertoire of each HLA molecule uncovered a frequent occurrence of certain
amino acid residues in these anchor positions; the recurring patterns were termed
“motifs” [62,75]. Although each HLA molecule has its own binding specificity and
anchor motifs, studies have shown that several HLA molecules within the same class
(class I or class II) share similar binding specificities with regard to those motifs. These
molecules are said to belong to the same ‘Supertype’, and the broad anchor motif that
describes the anchor motifs of each HLA member of the supertype cluster is referred to
as the ‘Supermotif’ [75,76]. For example, the HLA class I supertype A2, which includes
the HLA alleles A*02:01, A*02:02, A*02:03 and others, has a supermotif defined by
aliphatic hydrophobic residues (e.g. Alanine, Threonine) at position 2 and the C-terminus
of the target epitope.
In contrast to the serological and genetic nomenclature systems, HLA supertype
assignments are not standardized. Several research groups have defined HLA supertypes
based on the epitope-binding data of individual HLA alleles, which was generated via
different computational and empirical methods; consequently, no consensus assignment
of individual HLA alleles to a particular supertype exists [75,77]. With regard to HLA
class I alleles, the research group of Sidney and Sette [75,76,78] classified the HLA-A
and HLA-B loci alleles into 9 major supertypes: four for gene A, namely A1, A2, A3, and
A24, and five for gene B, namely B7, B44, B27, B58, and B62. This classification is in
general agreement with the results of others performed by the research groups of Tong
[79], Lund [80], and Hertz [81], with variations, if present, in the assignment of
individual alleles to supertypes and the splitting of supertypes to smaller groups; for
example, Lund et al. suggested the splitting of some of the alleles in the A1 supertype
into a new A26 supertype [62].
The functional categorization of HLA molecules into supertypes is very beneficial
for epitope-driven vaccine design. With regard to HLA class I supertypes, it was found
that 6 of the 9 supertypes proposed by the Sidney and Sette research group, namely A1,
A2, A3, A24, B7, and B44, account for most of the HLA-A and HLA-B alleles of five
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major ethnic groups in the general population (over 85% of HLA-A alleles and 40% of
HLA-B alleles in the Caucasian, North American Black, Hispanic, Chinese, and Japanese
ethnic groups). Practically, epitopes of those 6 supertypes can afford an average coverage
of 99.3% of any population, which means that an epitope-driven vaccine targeting
epitopes of all those supertypes at once can potentially be effective in any vaccinated
population [78].

2.6

The iVAX Immunoinformatics toolkit
iVAX (EpiVax Inc., RI, USA) is a web-based suite of immunoinformatics tools

for designing genome-derived T-cell epitope-driven vaccines [82]. The key tool of the
iVAX toolkit is called EpiMatrix, a frequency matrix-based T-cell epitope mapping tool
that has been used and validated for over a decade in in vitro and in vivo studies [23]. In
this section, a description of how EpiMatrix and the other tools of the iVAX toolkit that
were used in this project work will be discussed.

2.6.1 EpiMatrix:
Similar to other matrix-based T-cell epitope mapping tools, the EpiMatrix
algorithm is based on a collection of matrices for a set of class I and class II HLA
molecules (from here-on referred to also as ‘HLA alleles’ for simplicity instead of saying
‘HLA molecule coded by a given allele’). Within each matrix, a score is given to each of
the 20 amino acids at each pocket (position) in the binding cleft of the HLA molecule
based on the empirically-determined paucity or preponderance of that amino acid at that
position in a large set of natural epitopes of that molecule [23,78]. An example of one of
EpiMatrix’s frequency matricies is illustrated in figure 12. In a typical analysis aiming to
predict 9-mer binder epitopes, an input protein sequence is parsed into 9 amino acid
peptide frames, where each frame overlaps the last by 8 amino acids, and each frame is
scored for binding to a specific HLA allele additively using frequency scores derived
from the matrix corresponding to that allele, giving an allele-specific “raw score”. To be
able to compare binding affinities of a given peptide across several different alleles, the
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allele specific raw score is normalized according to a score distribution derived from a
randomly generated large set of peptides to give a Z-score (assessment score).
According to the Z-score scale, an epitope scoring 1.64 or higher is considered to
be a potential binder, as peptides scoring 1.64 or higher are usually from amongst the top
5% binders of a randomly analyzed peptide set; hence, such an epitope is considered
potentially immunogenic and is a good candidate for further testing. Furthermore,
epitopes scoring 2.32 or higher correspond to the top 1% binders of any analyzed peptide
set, and hence are the best candidates to be carried forward for further analysis in terms
of immunogenicity. Converting allele specific raw scores to Z-scores makes easier the
identification of promiscuous epitopes [23,78].

2.6.2 Conservatrix:
When designing vaccines against pathogens with highly mutable genomes such as
HCV and the Human Immunodeficiency virus (HIV), it is disadvantageous to include
highly mutable epitopes in the vaccine, despite the fact that they may be highly
immunogenic, as the pathogen will be able to escape the immune response directed
against those epitopes by mutating them. Accordingly, vaccine design must be directed
towards including highly conserved and immunogenic epitope targets in the vaccine;
such epitopes are usually parts of conserved amino acid sequences that play an important
structural or functional role in the pathogen’s life cycle and are less likely to be mutated
in the course of the pathogen’s evolution. To identify those epitopes, the iVAX toolkit
employs the “Conservatrix” tool, which parses input amino acid sequences into frames of
user-defined length, then scans the input dataset, which harbors several sequences
obtained from the different pathogen’s strains, for matching segments. The tool then
calculates the percent conservation of the analyzed segments across the input protein
sequences [23].
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2.6.3 EpiAssembler:
EpiAssembler is a tool that constructs MHC class II epitopes in an extended form
called “Immunogenic Consensus Sequence (ICS)” peptides using highly conserved,
promiscuously immunogenic, and overlapping MHC class II epitopes that were scored
for binding to MHC class II molecules using EpiMatrix and analyzed for conservancy
using Conservatrix [23]. EpiAssembler works by first selecting highly conserved and
promiscuously immunogenic (having Z-scores ≥ 1.64 for more than one MHC class II
alleles) 9-mer peptides, and then iteratively searching the rest of the EpiMatrix results
dataset for other highly conserved and promiscuously immunogenic peptides that overlap
the N- and C-termini of the initial “core” peptide in order to use those peptides to extent
the length of the constructed ICS. In the case where more than one overlapping peptides
are identified, the one with the highest conservancy and promiscuous immunogenicity is
selected by EpiAssembler to extend the ICS. This process of ICS extension is repeated
until either no more overlapping peptides are found in the dataset, or until the userdefined ICS length is reached [23,83]. An illustration of how EpiAssembler works is
given in figure 13.
Apart from choosing the most conserved and promiscuously immunogenic MHC
class II epitopes for vaccine design, which would potentially increase the vaccine’s target
population coverage and its ability to trigger a protective immune response,
EpiAssembler has the advantage of enabling the design of a vaccine construct that
delivers an ‘antigenic payload’ which would otherwise be very expensive to develop
using conventional methods, as different variants of each antigen will have to be included
in the vaccine [23].

2.6.4 JanusMatrix:
As aforementioned, the inclusion of T-cell epitopes in the vaccine construct that
bear similarity to autologous epitopes from the human proteome may either result in
triggering an autoimmune response against self, or in triggering a suppressive immune
response that would decrease the vaccine’s efficiency; accordingly, it is advised that such
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epitopes not be included in the vaccine [23,60]. Epitopes that are putatively cross-reactive
with self can be identified in silico using the JanusMatrix tool.
JanusMatrix is a tool that identifies T-cell epitopes from the human proteome
(genome), protein sequences of the human microbiome, and/or human bacterial and viral
pathogen proteomes that are potentially cross-reactive with T-cell epitopes of interest;
specifically by identifying T-cell epitopes from those proteomes and protein sequences
that bear identical T-cell receptor (TCR)-facing amino acid residues to those of the
epitopes of interest [84]. The tool works by dividing putative 9mer T-cell epitopes
predicted by the EpiMatrix tool into TCR-facing residues (referred to also as the
“epitope”) and HLA-binding residues (referred to as the “agretope”) based on rules
defined in literature, and then searching for potentially cross-reactive epitopes across
user-selected protein databases from those that have been pre-uploaded to the tool that
bear identical TCR-facing residues and are predicted to bind the same HLA molecule as
the putative T-cell epitopes of interest, regardless of the existence of discrepancies in the
agretope [84]. According to literature, the TCR-facing residues of HLA class I 9mer
epitopes are residues number 4, 5, 6, 7, and 8, while those of HLA class II epitopes are 2,
3, 5, 7, and 8 [85]. Figure 14 displays a 3D model of a T-cell epitope in association with
both the HLA molecule and the TCR.
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3. PROJECT AIM & OBJECTIVES
The aim of this project is to identify, in silico, a set of highly immunogenic and
conserved T-cell epitopes from within the HCV-4 proteome as putative targets for an
epitope-driven vaccine for HCV-4. The objectives of the project are as follows:

1. To use the iVAX immunoinformatics toolkit (EpiVax Inc., RI, USA) to identify
highly conserved and immunogenic T-cell epitopes from within 46 non-redundant
HCV-4 proteomes, and assess their homology to epitopes derived from the human
genome.

2. To retrospectively validate the HLA binding predictions for those epitopes by
searching for records of HLA binding assays or T-cell assays performed on those
epitopes in previous literature in the context of other HCV genotypes on the
Immune Epitope Database (IEDB).

3. To perform a pilot in vitro HLA binding assay on selected HLA class II ICS
peptides (epitopes), and compare the results with those of the retrospective
validations for the same peptides.

4. To assess the conservation of a selected set of the identified epitopes in newly
partially re-sequenced HCV genomes derived from the Egyptian Population as an
assessment of the HCV subtype coverage that these epitopes would provide if
they were to be included in population-specific vaccine targeting the Egyptian
population.
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4. METHODOLOGY
4.1

HCV-4 Genomes Collection
46 non-redundant HCV genotype 4 full genomic sequences were retrieved from

the Los Alamos HCV sequence database (LANL) [86]; their accession numbers were also
matched on the Genbank database, these being: DQ418785, DQ418782, DQ418783,
DQ418784, DQ418787; DQ418788; DQ418789, DQ516084, DQ988073, DQ988074,
DQ988075, DQ988076, DQ988077, DQ988078, DQ988079, GU814265, NC_009825,
FJ025854, FJ025855, FJ025856, FJ462435, FJ462436, DQ418786, DQ516083,
EU392172, FJ462437, EF589160, EF589161, EU392169, EU392170, EU392174,
EU392175, FJ462432, EU392171, EU392173, FJ462438, FJ839870, FJ462433,
FJ462441, FJ462440, FJ462431, FJ462434, FJ462439, FJ839869, HQ537008, and
HQ537009. The amino acid sequences of the HCV polyprotein genes corresponding to
those genomic sequences were downloaded in FASTA format and modified to a format
compatible with the iVAX toolkit server, whereby all the single letter ambiguous amino
acid codes B, Z, and J, which stand for Asparagine/Aspartic acid, Glutamine/Glutamic
acid, and Leucine/Isoleucine, respectively, and the single letter amino acid codes U and
O, which stand for the 21st and 22nd identified amino acid residues Selenocysteine and
Pyrrolysine, respectively, were replaced with the single letter ambiguous amino acid code
X, which declares the amino acid residue as unspecified. After their modification, the 46
protein

sequences

where

uploaded

to

the

iVAX

toolkit’s

website

(https://ocs.epivax.com/ivax_ntd/) as a single file bearing the “.PEP” file extension that is
required for the sequences to be identified as proteins. More information on the 46 HCV4 sequences is provided in table 3.

4.2

HLA Class I and Class II Epitopes Identification and Selection
After uploading the sequences onto the iVAX server, the tools of the iVAX-

toolkit were used in concession to identify and narrow down the selection of HLA class I
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and II epitopes from the HCV-4 sequences to a set that can be putatively included in the
final vaccine product.

4.2.1 Conservation Analysis:
The Conservatrix tool was used to parse the input sequences into 9-mer peptide
frames and analyze the conservation of those frames across the 46 amino acid sequences.
The 9-mer peptide frames represent putative HLA class I epitopes and the core regions of
putative HLA class II epitopes.

4.2.2 HLA Class I and II Epitope Prediction:
After performing the conservation analysis, the EpiMatrix tool was used to
predict the binding of the parsed 9-mer frames to the six HLA class I alleles A*01:01,
A*02:01, A*03:01, A*24:02, B*07:02, and B*44:03 which belong to the 6 supertypes
A1, A2, A3, A24, B7, and B44 respectively, and the eight HLA class II DR alleles
DRB1*01:01, DRB1*03:01, DRB1*04:01, DRB1*07:01, DRB1*08:01, DRB1*11:01,
DRB1*13:01, and DRB1*15:01. The phenotypic frequencies of those HLA class I and II
alleles cover >90% of any human population regardless of its ethnic origin, potentially
allowing the vaccine to be effective in any vaccinated population [78,95]. It is important
to note here that the DR molecules are referred to by the names of the DRB1 alleles
which code for the polymorphic β chains of the molecules.
After obtaining the results of the analysis, only those peptide frames that have Zscores ≥ 1.64 for binding to a HLA class I allele and are fully conserved in at least 42 out
of the 46 sequences (>90% conservancy) were chosen for further analysis. As for peptide
frames scored for binding to HLA class II alleles, the EpiAssembler tool was used to
construct extended Immunogenic Consensus Sequence peptides (ICS) from those frames.
Before executing the analysis, EpiAssembler was set to only extend core peptides with
peptides that overlap with it by at least 4 amino acids at either the N- or C-termini, and to
extend the ICS to a maximum length of 21 amino acids. It was also set to construct ICS
peptides whose component core 9-mer segments cover, collectively, at least 90% of the
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46 uploaded HCV polyprotein sequences in terms of conservation, and to only accept the
construction of ICS peptides that have a minimum EpiMatrix Cluster Immunogenicity
score of 10. The EpiMatrix Cluster Immunogenicity score is derived from the number of
EpiMatrix “hits” (scores ≥ 1.64 per allele) normalized for the length of the ICS peptide; a
score of ICS 10 or higher indicates that the ICS possesses a significant immunogenic
potential.

4.2.3 Homology to Self Analysis:
In order to avoid a suppressive immune response to the sequences selected for the
vaccine, or autoimmune adverse effects due to the induction of immune response to
epitopes cross-conserved with self in the final vaccine product, the selected HLA class I
epitopes and HLA class II ICS peptides were assessed for homology to the human
genome using the JanusMatrix tool, where the reviewed human Uniprot protein database
that was per-uploaded to the tool server was scanned for cross-reactive epitopes within
the human genome that bear identical TCR-facing AA residues and are predicted by
EpiMatrix to bind to the same alleles for which the analyzed epitopes are predicted to
bind to.

4.3

Epitope Mapping on the HCV Genome
The regions of the HCV genome harboring the selected epitopes and their exact

locations were determined by aligning the amino acid sequences of the epitopes with the
amino acid sequence of the polyprotein gene of the HCV genotype I reference strain H77
(Accession number: NC_004102) using the “Sequence locator” tool of the Los Alamos
HCV sequence database (LANL) [86].

4.4

Retrospective Validation of the EpiMatrix Predictions
To investigate whether the selected HLA class I epitopes and constructed HLA

class II ICS peptides were tested before in vitro in previous literature for HLA binding,
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cell-surface presentation, and/or their ability to elicit an immune response, the Immune
Epitope Database (IEDB), a large repository of immune epitope data manually curated
from peer reviewed literature, patents, and direct submissions from companies and
institutions [21], was queried for each of the selected epitopes and ICS peptides. Using
the home page search tool (http://www.iedb.org/), the database was queried for available
data on experiments for MHC binding and elution (MHC Ligand assays), and T-cell
response performed on epitopes/peptides that exactly match the query sequences or
harbor those sequences as substrings. For the HLA class II ICS search, peptides that are
70-90% identical to the constructed ICS peptides were also included in the search criteria.
Before querying the database, the immune recognition context parameters were restricted
to MHC class I or II-restricted matches (depending on the queried epitope), and Homo
sapiens (id:9606) selected as the host organism for T-cell assay searches.

4.5

HLA Class II in vitro Binding Assay
As a pilot in vitro validation of the predictions performed by the iVAX toolkit, 4

MHC class II ICS peptides (table 10) were assessed for binding to 4 different purified,
soluble HLA class II DR alleles (molecules), namely DRB1*01:01, DRB1*04:01,
DRB1*07:01, and DRB1*15:01 in a competition binding assay against biotinylated
standards. The presence/absence and strength of peptide binding to a given HLA
molecule are determined via determining the concentration of test peptide required to
prevent 50% of standard peptide from binding to the assayed HLA molecule (IC50).
The overall strategy of the experiment involved each ICS peptide undergoing the
assay for each HLA allele in triplicates of 6 dilutions of the peptide in four 96-well
reaction plates, one plate for each HLA allele. For each reaction plate, positive and
negative control reactions were performed in triplicates. The positive control reactions
involved the reaction of HLA allele-specific standard peptides with their respective HLA
molecules, giving a “maximum fluorescence” reading for the binding of the standard
peptide. The negative control reactions involved the addition of only the HLA molecules
to the reaction plates without the addition of any peptides.
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At first, lyophilized pellets of the test ICS peptides (21 st Century Biochemicals,
MA, USA) were solubilized in amounts of Dimethyl Sulfoxide (DMSO) (Sigma-Aldrich,
MO, USA) pre-determined by the manufacturer to obtain a final concentration of 100 μM
of each peptide. After solubilizing the test peptides, 30 mL of reaction Master Mix were
prepared by mixing 30 mL of Citrate-phosphate buffer pH 5.4 (prepared by mixing 278
mL of 2M Sodium phosphate and and 222 mL of 1M Citric acid (Sigma-Aldrich, MO,
USA)), 300 μL of 1 mM PefaBloc (Roche Applied Science, Penzberg, Germany) and
225mg of Octyl-β-D-Glucopyranaside (OG) (MP Biomedicals, OH, USA). After
preparing the master mix, 6 dilutions of the 4 ICS peptides in the master mix were
prepared in a tube rack composed of 6-rows x 4-columns, where each column was
designated for one of the 4 ICS peptides. 800μL of master mix solution were transferred
to all the rows of the tube rack except for the top row, which received 1170μL of
solution. To each of the 4 tubes in the top row, 46.8μL of the solubilized ICS peptide
solutions was added, one peptide for each tube. After that, 370.4μL of the master mixICS peptide mixtures in the top row were serially transferred across the remaining 5
rows, diluting the ICS peptide-master mix solution by a factor of 3.16 across the tubes.
The dilution factor was predetermined and pre-optimized by EpiVax Inc., and excess
amounts of master mix and peptide solutions were added to the tube rack based on
calculations performed according to a project work-plan provided by EpiVax Inc. The
final dilutions of each peptide in each of the reaction plates across the top 6 rows were:
100 μmol/mL, 31.6 μmol/mL, 10 μmol/mL, 3.16 μmol/mL, 1 μmol/mL, and 0.316
μmol/mL.
After preparing the ICS dilutions, triplicates of 25μL of each dilution of each
peptide were transferred to the top 6 rows of four 96-well reaction plates (Fisherbrand,
Loughborough, UK). 25μL of master mix alone were transferred to the first six wells of
the bottom row of the four reaction plates where the positive and negative control
reactions were carried out. To prepare the HLA molecules required for performing the
binding reactions, purified HLA-DRB1 monomers of the molecules of interest (Benaroya
Research Institute, WA, USA) were each diluted in 3mL of the prepared master-mix
based on calculations performed according to the project work-plan provided by EpiVax
Inc. The exact amounts of monomers diluted were: 0.5μL of DRB1*01:01 monomers
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from a stock solution with a concentration of 2.5mg/mL, 0.92μL of DRB1*04:01
monomers from a stock solution with a concentration of 1.3mg/mL, 0.8μL of
DRB1*07:01 monomers from a stock solution with a concentration of 1.5mg/mL, and
0.67μL of DRB1*15:01 monomers from a stock solution with a concentration of
1.8mg/mL. After mixing the aforementioned amounts with 3mL of master-mix each,
25μL of each diluted monomer solution were directly added to its respective negative
control wells of the prepared reaction plates, causing the final reaction volume in those
plates to be 50μL.
To prepare the standard biotinylated peptides that will compete with the ICS test
peptides for HLA binding, aliquots from stock solutions of the standard peptides (21 st
Century Biochemicals, MA, USA) were diluted in the prepared HLA monomer-master
mix mixtures, where each HLA monomer was mixed with a specific standard peptide.
The standards peptides were diluted in such a way that their final concentrations in the
wells of the reaction plates became 0.025μmol/mL. Precisely, 6μL from 25μM stock
solutions of the YAR, Tetanus Toxin, and MBP protein standard peptides were diluted in
the 3mL solutions of the DRB1-04:01, DRB1-07:01, and DRB1-15:01 monomers
respectively, and 30μL from a 5μM stock solution of the Influneza A virus Hemaglutininderived standard peptide was diluted in the 3mL solution of the DRB1-01:01 monomer.
After preparing the biotinylated peptide-HLA mixtures, 25μL of each mixture were
transferred to the 96-well reaction plates in all the wells containing the test peptides and
in the positive control wells, causing the total reaction volume in all those cells to be
50μL. As aforementioned, each reaction plate is only designated for one kind of HLADRB1 allele. After that, the reaction plates were covered and incubated overnight at 37oC
to allow the binding reactions to take place.
After putting the reaction plates in incubation, four ELISA plates were prepared
for capturing the HLA-DR monomers with their bound peptides by coating four 96-well
EIA/RIA plates (Corning, NY, USA) with L243 anti-HLA-DRA antibodies (BioXCell,
NH, USA). First, a 1000-fold dilution of the L243 antibodies in Borate buffer pH 8.2
(prepared by dissolving 1.19g of Sodium tetraborate decahydrate (Sigma-Aldrich, MO,
USA) in 250mL MilliQ water) was prepared from an antibody stock solution of
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concentration 10.36mg/mL. Then, 100μL of the prepared antibody solution was
transferred to each well of the four ELISA plates, and the plates were covered and
incubated overnight at 4oC.
On the following day after incubation, the contents of the ELISA plates were
discarded, and the plates were washed three times with Phosphate Buffer Saline PBS0.05% Tween 20 (prepared by mixing 500mL of 10x Dulbecco’s PBS (Life
Technologies, CA, USA) with 2.5mL of Tween 20 (Sigma-Aldrich, MO, USA) in 4.5L
of MilliQ water) using an automated plate washer. 40μL of 50mM Tris Neutralization
buffer (prepared by diluting 1.5mL of 1M Trizma HCL (Sigma-Aldrich, MO, USA) in
28.5mL of MilliQ water) were then added to each well of the ELISA plates. After that,
40μL of HLA monomer-peptide reaction mixtures from each well of the overnight
incubated reaction plates were transferred to their corresponding wells in the ELISA
plates containing the neutralization buffer. The ELISA plates were then incubated at 37 oC
for 2.5 hours.
After the 2.5 hour incubation, the contents of the ELISA plates were discarded,
and the plates were washed three times with PBS-0.05% Tween 20 using an automated
plate washer. A 1000-fold diluted solution of Streptavidin-Europium in Assay buffer was
then prepared, where 10μL of Europium-labeled Streptavidin (Perkin-Elmer, MA, USA)
were diluted in 10mL of DELFIA Assay buffer (Perkin-Elmer, MA, USA). 100μL of
diluted Streptavidin-Europium solution were then transferred to each well of the ELISA
plates harboring captured HLA molecules. The plates were then covered and placed in
the dark for 1 hour at room temperature. After that, the contents of the plates were
discarded, and the plates were washed three times with PBS-0.05% Tween 20 using an
automated plate washer, followed by 2 washes with PBS alone to remove any bubbles.
After that, 100μL of Delfia Enhancement buffer (Perkin-Elmer, MA, USA) were added to
each well of the ELISA plates, and the plates were again covered and placed in the dark
for 10 minutes at room temperature.
After that, the plates were inserted into a Victor3V Microtiter Plate Reader
(Perkin-Elmer, MA, USA), and the fluorescence of Europium was read under the
Europium setting. The resultant raw data file was exported in Excel format and stored for
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IC50 calculations, which were performed using the SigmaPlot 11.1 software package
(Systat Software Inc., IL, USA) via constructing four parameter logistic curves.

4.6

Conservation Analysis in newly partially re-sequenced HCV
genomes from the Egyptian Population
In an attempt to assess whether the predicted T-cell epitopes are conserved in the

HCV strains currently circulating in the Egyptian population, a pilot conservation
analysis has been performed on a group of selected epitopes in partially re-sequenced
HCV genomes newly isolated from the Egyptian population; epitopes found to be highly
conserved are, as aforementioned, good candidates for population-specific vaccine
development. Specifically, the Core, NS3, NS4B, and NS5B regions of the HCV genome
-the regions harboring most of the identified epitopes as explained in the results sectionwere targeted for re-sequencing and conservation analysis. The steps of a protocol
outlined in Yao et al. (2005) [96] were followed for the Reverse Transcription
Polymerase Chain Reaction amplification (RT-PCR) and nested PCR amplification of the
target sequences. The amplification step was followed by Sanger sequencing of the
amplified sequences and the in silico conservation analysis of the identified epitopes that
they harbor/cover.

4.6.1 Primer Design:
At first, oligonucleotide sense and antisense primers were designed de novo to be
used in the RT-PCR amplification and Sanger sequencing of the target regions. Since the
optimal DNA target read length for Sanger sequencing is 700-900 bp long [97], the NS3
(1893 bp long) and NS5B (1776 bp long) regions were accordingly each divided into two
frames overlapping by ~140 bp for amplification and sequencing; the Core (573 bp) and
NS4B (783 bp) regions, however, were targeted for sequencing in single frames, making
the total number of target HCV RNA frames to be amplified and sequenced 6 out of each
isolated HCV genome. To design the primers, the 46 HCV-4 sequences retrieved for
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epitope prediction (table 3) were aligned by multiple sequence alignment using the
Clustal Omega online tool (http://www.ebi.ac.uk/Tools/msa/clustalo/) [98]; the resultant
multiple alignment file was then viewed using the ClustalX 2.1 program [99] to allow for
the visual identification of the most highly conserved RNA sequences flanking the 6
target regions to be analyzed in order to be used for primer design. Candidate sequences
were then analyzed using the freely available online OligoAnalyzer 3.1 tool
(http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer/)

(Integrated

DNA

Technologies Inc.) with regards to melting and annealing temperatures (T m and Ta
respectively), Guanosine and Cytosine percentage (GC content), and the formation of
hair-pin structures, self-dimers, and heterodimers between sense and antisense primers.
To the best extent possible, all primers were designed to have: (1) a GC content of
40%-60%, which would decrease the likelihood of non-specific priming caused by the
strong bonding between G and C nucleotides, (2) a maximum negative Gibbs free energy
(ΔG) value of -3 kcal/mol associated with intra-molecular hairpin structure formation and
-6 kcal/mol associated with inter-molecular homo and heterodimer structure formation
between primers; larger negative values for ΔG associated with these structures may
facilitate their formation at the primer annealing temperatures and consequently decrease
the availability of these primers for use in the amplification reaction, eventually leading
to a lower product yield, and (3) a difference in annealing temperature between sense and
anti-sense primers of not more than 5 degrees [100]. Where possible, nested primers were
designed in order to carry out nested PCR reactions using the amplicon products of the
RT-PCR reactions; this would increase the yield and specificity of the amplification
reactions. Following their design, the primers were ordered for synthesis (Bioneer Inc.,
Daejeon, Republic of Korea). A list of the primer sequences and information about their
sizes, locations, melting temperatures, and amplicon sizes are listed in table 4. An
example of the alignment of one of the primers with the 46 HCV-4 sequences is
illustrated in figure 15.
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4.6.2 Sample Collection:
Left-over anonymous serum samples positive for HCV RNA isolated from the
Egyptian population were obtained from the sample archives of private diagnostic labs
collaborating with our research group “Novel Diagnostics and Therapeutics” for HCV
RNA extraction after obtaining the approval of the Internal Review Board of the
American University in Cairo.

4.6.3 HCV RNA Extraction:
Viral RNA was extracted using the QIAamp® Viral RNA Mini kit (Qiagen,
Limburg, Netherlands) according to the manufacturer’s “spin column” extraction
protocol. First, 140 μL of each sample were incubated for 10 minutes at room
temperature with 560 μL of buffer AVL mixed with 5.6 μL of carrier RNA – AVE buffer
solution (1 μg/μL). Buffer AVL contains guanidine thiocyanate for lysis of the viral
particles and denaturation of RNases in the serum sample. The carrier RNA binds to the
extracted viral RNA, enhancing its subsequent binding to the silica-gel membrane of the
spin extraction columns and protecting it from degradation by RNases in the unlikely
event that these RNases escape denaturation by buffer AVL. Before mixing with buffer
AVL, carrier RNA was first dissolved in buffer AVE, which is RNase-free water
containing 0.04% sodium azide as a preservative for microbial growth prevention.
Following the 10 minutes incubation, 560 μL of absolute ethanol were added to each
sample-AVL-carrier RNA mixture. After that, 630 μL of each mixture were transferred to
spin columns fitted inside empty collection tubes. The spin columns were then
centrifuged for 1 minute at 8000 rotations per minute (r.p.m.) at room temperature using
a 2-16PK centrifuge (Sigma, Osterode, Germany); this step was repeated a second time
with the remaining 630 μL of sample mixture. Collection tubes containing the filtrate
were discarded, and the spin columns were placed in new collection tubes.
In the following step, 500 μL of AW1 wash buffer were added to each spin
column, followed by a 1 minute centrifugation at 8000 r.p.m. at room temperature. The
filtrate was then discarded and a new collection tube was added. 500 μL of AW2 wash
50

buffer were then added to each spin column, followed by a 3 minute centrifugation at
14,000 r.p.m. at room temperature. The wash buffers purify the viral RNA in the sample
from other contaminants. After discarding the collection tubes with the filtrate from the
last centrifugation, the spin columns were then placed in 1.5 mL microcentrifuge tubes
and 60 μL of nuclease-free water were added to the columns. After one minute incubation
at room temperature, the spin columns were centrifuged for 1 minute at 8000 rpm at room
temperature, and the eluate containing the extracted and purified viral HCV RNA was
retained.

4.6.4 Amplification by RT-PCR:
Following HCV RNA extraction, the target Core, NS3, NS4B, and NS5B regions
were amplified by RT-PCR using the Access RT-PCR System (Promega, WI, USA) and
the set of external primers (not nested) listed in table 4. Six reaction mixtures for each
sample, 25 μL each, were prepared for the amplification of the target regions. To prepare
the reaction mixtures, the following components were added to 0.5 mL PCR tubes: (1) 5
μL of AMV/Tfl Reaction Buffer (5X), (2) 0.5 μL of dideoxy-nucleotide triphosphate
(dNTP) mixture (10mM of each nucleotide), (3) 1 μL of Magnesium Sulfate (MgSO 4)
solution (25mM), (4) 2.5 μL of each forward and reverse primers (10 pmol/μL), (5) 0.5
μL of Avian Myeloblastosis Virus Reverse Transcriptase (AMV RT) (5u/μL), (6) 0.5 μL
of thermostable Thermus flavus (Tfl) DNA polymerase (5u/μL), (7) 10 μL of extracted
HCV RNA sample, and (8) nuclease-free water up to 25 μL. Positive control reactions
were prepared by adding the same components to the reaction tubes with the exception of
adding of 2 μL positive control RNA with carrier (1 × 106 copies) and 3.3 μL of control
upstream and downstream primers (50 pmols) provided with the kit instead of the HCV
RNA template and the de novo designed primers respectively. For negative control
reactions, nuclease free water was used instead of the positive control RNA with carrier;
the control upstream and downstream primers were also used for the negative reactions.
After preparing the reaction mixtures, the PCR tubes were placed into the Veriti
90-well Thermal Cycler (Applied Biosystems, CA, USA). The PCR cycling profile was
set to start with one cycle for first strand (cDNA) synthesis by reverse transcription at
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45oC for 45 minutes, followed by one cycle for the denaturation of the AMV RT at 94 oC
for 2 minutes. After that, the samples were subjected to 45 cycles of PCR amplification
which consisted of: (1) a 30 second template denaturation step at 94oC, (2) a 1 minute
primer annealing step at the optimized temperature of 45 oC, (3) a 2 minute new stand
extension step at 68oC. A final extension step at 68oC was performed for 7 minutes to
allow the extension of truncated products and enhance the quality of the results.

4.6.5 Nested PCR:
To increase the specificity and yield of the amplification reactions, nested PCR
was performed using the internal nested PCR primers from table 4 and amplicons
obtained from the RT-PCR step as a template. Nested PCR was performed using either
the GoTaq® Colorless Master Mix (Promega, WI, USA) kit or the Maxima Hot Start
PCR Master Mix (Thermo Scientific, MA, USA). To prepare the reaction mixtures, the
following components were added to 0.5 mL PCR tubes: (1) 25 μL Master mix
containing a Taq DNA polymerase, (2) 2 μL of each of the forward and reverse primers,
(3) 10 μL of the RT-PCR amplicon products as templates, and (4) nuclease free water up
to 50 μL.
After preparing the reaction mixtures, the PCR tubes were placed into the Veriti
90-well Thermal Cycler (Applied Biosystems, CA, USA). The PCR cycling profile was
set to start with one denaturation step at 95oC for 2 minutes, followed by 35 cycles of: (1)
a 30 second denaturation step at 95oC, (2) a 1 minute primer annealing step at optimized
annealing temperatures for each primer pair, and (3) a 45 second DNA strand extension
step at 72oC. A final extension step for 5 minutes at 72oC was performed before stopping
the reaction. The optimized annealing temperatures that gave the best results for each
primer pair were: (1) 45oC for the AF and ARN pair, (2) 47oC for the DF and DRN pair, and
(3) 50oC for the pairs BFN and BR, CFN and CRN, and EF and ERN. No optimized annealing
temperature was determined for the primer pair F F and FR since amplification reactions
utilizing this pair did not yield any results by RT-PCR (as will be explained in the results
section).
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The results of the amplification were analyzed by gel electrophoresis on a 1%
agarose gel. The gel was prepared by dissolving 2g of Seakem® LE Agarose (Lonza,
Basel, Switzerland) and 6 μL of Ethidium Bromide solution (10mg/mL) (Promega, WI,
USA) in 200 mL of 1X Tris-Borate-EDTA buffer (Lonza, Basel, Switzerland) and then
allowing the mixture to solidify. After gel solidification, 5 μL of a 100 bp DNA Ladder
(Promega, WI, USA) mixed with 2 μL loading dye (provided with the ladder) were
loaded into the first well. 5 μL of each of the samples’ amplicons were added to the other
wells mixed with 2 μL loading dye. The gel was then run at 95V for 1 hour in 1X TBE
running buffer. The amplicon bands were then visualized on an ECX-20.M
transilluminator (Vilber Lourmat, Marne-la-Vallée, France); images of the gel were taken
using a Samsung S2 8.0 megapixel mobile phone camera (Samsung, Seoul, South Korea).
The remainder of the sample amplicons was stored at -20oC to be later sequenced.

4.6.6 PCR Purification and Sanger Sequencing:
Purification of the PCR sample amplicons was performed at Sigma Scientific
Services Co. (Cairo, Egypt) using the GeneJET™ PCR Purification Kit (Thermo
Scientific, MA, USA) according to the manufacturer’s instructions; where required, gel
extraction of the amplicons was performed using the same purification kit. Sanger
sequencing of the purified samples was performed at GATC Biotech AG (Constance,
Germany) using an ABI 3730xl DNA Analyzer (Applied Biosystems, CA, USA);
sequencing was performed using the forward and reverse primers for each sample.

4.6.7 Conservation Analysis:
After the results of the Sanger sequencing were retrieved, the sequencing
chromatograms were viewed using the BioEdit sequence alignment editor (Ibis
Biosciences, CA, USA). Base calls made based on broad peaks or regions with strong
background “noise” at the 5’ and 3’ ends of the sequences in the chromatogram were
truncated from the nucleotide sequences. The truncated sequences were then analyzed
using the Basic Local Alignment Search Tool (BLAST) of the National Center for
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Biotechnology Information website (NCBI) (http://blast.ncbi.nlm.nih.gov/Blast.cgi);
where the blastn and blastx programs were used in their default settings to confirm the
identities of the new sequences. Once confirmed, consensus amino acid sequences of the
re-sequence regions were assembled by aligning the forward and reverse sequenced
frames of each region using the Clustal X 2.1 software. Following sequence assembly,
the conservation of the epitopes across the consensus sequences that cover the locations
of those epitopes on the HCV-1a (H77) sequence was assessed using the Epitope
Conservancy Analysis tool of the Immune Epitope Database (IEDB) Analysis Resource
website (http://tools.immuneepitope.org/tools/conservancy/iedb_input).
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5. RESULTS
5.1

HLA Class I Epitope Identification and Validation

5.1.1 iVAX analysis results:
The Conservatrix and EpiMatrix tools parsed and scored a total of 32,286 9-mer
peptide frames from the 46 polyprotein sequences. From those, 151 peptides that are fully
conserved in at least 42 out of the 46 sequences (90% conservancy) and that have a Zscore ≥ 1.64 were chosen for further analysis; peptides with Z-scores ≥ 1.64 for a given
allele are most likely to be binders of that allele. The JanusMatrix analysis revealed that
90 out of the 151 selected epitopes have no cross-reactive hits in the human genome. The
remaining 61 epitopes do have cross-reactive epitopes ranging from 1 to 9. Accordingly,
the 90 epitopes with no cross-reactive hits were selected as good putative candidates for
epitope-driven vaccine design against HCV-4.
Analysis of the locations of the 90 epitopes revealed that 23 epitopes are located
in the Core region, 21 in the NS3 region, 14 in the NS4B region, 15 in the NS5B region,
5 in the NS5A region, 4 in the E2 region, 2 in the NS2 region, and 1 in the E1 region. No
epitopes were found to be located in the p7 and NS4A regions. The 5 remaining epitopes
were found to be located at the junctions between the sequences of non-structural
proteins. An example of the results of the binding predictions for 7 of the 90 selected
peptides and their percent conservation and locations in the HCV-4 genome are listed in
table 5.

5.1.2 Retrospective Validation Results:
The IEDB search revealed that 20 out of the 90 selected 9-mer epitopes have no entries
for previously performed tests for MHC binding, cell-surface presentation, nor the ability to

elicit a CD8+ immune response in previous literature; indicating that those epitopes may
be novel and have not been previously characterized. As for the remaining 70 epitopes,
entries have been found for previously performed tests for HLA binding in vitro and/or the
ability to elicit a CD8+ T-cell immune response via in vitro T-cell assays. No entries for
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MHC elution assays were found for any of the queried epitopes. The 70 epitopes can be
divided into three categories based on the IEDB results: (1) a category of 20 epitopes that
tested positive in HLA binding and/or CD8+ T-cell assays as 9-mer peptides (exact match
to the identified sequences), (2) a category of 22 epitopes that tested positive in HLA
binding and/or CD8+ T- cell assays as substrings of longer peptides, and (3) a category of
28 epitopes that only tested negative in HLA binding and/or T-cell assays as 9-mer
peptides and/or as substrings of longer peptides.
From the first category of 20 epitopes that tested “positive” for HLA binding
and/or the ability to trigger a CD8+ T-cell response in assays where the 9-mer epitope
itself has been used as the test peptide or has been empirically identified as the optimal
epitope causing the positive response from within a larger tested peptide, 9 epitopes were
previously tested for both HLA binding and the ability to trigger a CD8 + T-cell response,
4 were tested for HLA binding only, and 7 were tested for the ability to trigger a CD8+ Tcell response only. For all the assays performed on the 20 epitopes, the HLA restricting
allele was determined and listed in the epitopes’ IEDB entries. The results of the HLA
binding assays performed in previous literature on 4 of the epitopes listed in table 5 are
listed in table 6 as an example of the returned search results. In table 7, the results of the
IEDB search for previously performed T-cell assays also on 4 of the epitopes listed in
table 5 are displayed; only the entries where the epitope was tested as a 9-mer in previous
literature are listed.
The last column to the right of table 7 describes the methods by which the authors
of the listed references demonstrated the HLA allelic restrictions of the test epitopes; the
methods in the table are represented as one number and one letter whose meanings are
described in table 8. Each number represents a “method” by which the HLA allelic
restriction has been demonstrated, and each letter represents the basis upon which the
authors have predicted/known the tested epitopes to be restricted by the listed alleles
prior to the execution of the assays. The methods of demonstration of HLA restriction
can be categorized into three methods: the first method involves the use of different lines
of antigen presenting cells or target cells that bear matching and mismatching sets of
HLA alleles to the assayed CD8+ T-cells from individual(s) carrying a certain HLA allele
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X (HLA-X+); if the cells are stimulated by APCs or target cells carrying the same X
allele but not by ones lacking it, this confirms the restriction of the test epitope by that
allele. The second method involves the use of HLA tetramers or APCs expressing only a
single HLA allele (e.g. murine cells expressing a human HLA allele) to trigger the T-cell
response; if the response is positive, this confirms the restriction of the test epitope by the
single allele type present in the assay. The third method involves the use of only APCs
with HLA alleles matching those of the assayed T-cells (usually autologous) to trigger a
T-cell response; while this method is not sufficient to demonstrate HLA restriction, its
repetition in more than one assay by more than one author using different patient cohorts
and different testing methods increases the likelihood of the claimed HLA restriction
being true. In addition to the methods of demonstration of restriction, authors of the listed
assays usually have reasons to predict/know the HLA restriction of the epitope prior to
performing the assay; these include in silico binding predictions, the presence of the HLA
binding motif in the epitope, an in vitro HLA binding assay, a previous citation
mentioning/demonstrating HLA restriction, or a combination thereof. Where the reason
for prediction/knowledge is not listed in table 7, it means that the reason has not been
clearly mentioned, or that the assay was performed on pools of peptide epitopes that have
not been previously characterized.
For 11 out of the 16 epitopes that tested positive in T-cell assays as 9-mer
peptides, the listed HLA restrictions were demonstrated at least once by methods “1”
and/or “2” in previous literature, in addition to the demonstration of some of those
restrictions by in vitro HLA binding assays. As for the 5 remaining epitopes, the listed
HLA restrictions were demonstrated only by method “3” in previous literature, which on
its own is not sufficient to empirically demonstrate HLA restriction. However, for two of
those epitopes the listed HLA restrictions were empirically demonstrated prior to
performing the T-cell assays via in vitro binding assays; which in itself can validate the
EpiMatrix binding predictions. As for the 3 other epitopes, the listed HLA restrictions
were predicted prior to performing the T-cell assays due to the presence of their binding
motifs within those epitopes; accordingly, further empirical demonstration of HLA
restriction for those epitopes is required.
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When the results of the EpiMatrix binding predictions for the aforementioned 20
epitopes were compared to their empirically demonstrated HLA allelic restrictions, it was
observed that the EpiMatrix predictions for 18 out of 20 of those epitopes were
retrospectively validated by the empirical results. This is because the HLA alleles that
were empirically demonstrated to restrict those epitopes had Z-scores ≥1.64, or belonged
to the same supertypes of the alleles that scored ≥1.64 in the EpiMatrix predictions.
Furthermore, the HLA allele A*24:02 which was empirically proven to restrict the
epitope ITYSTYGKF had an EpiMatrix Z-score of 1.4, which although is not ≥1.64
predicts that the epitope is from amongst the top 10% binders of the allele from within a
random set of peptides. Accordingly, it can be said that the EpiMatrix predictions
performed in this analysis were retrospectively validated for 19 out of the 20 epitopes that
have been positively tested as 9-mers for HLA binding and/or the ability to trigger a
CD8+ T-cell response in human subjects. As for the epitope QYLAGLSTL which was
empirically demonstrated to bind to the allele A*02:01, the empirical results did not
validate the EpiMatrix prediction, where the allele was given a Z-score of 0.95. However,
the binding of that epitope to its highest scoring allele, A*24:02 (Z-score = 2.73), was not
tested in vitro; empirical validation of binding to this allele is still required. These results
also take into account the 3 epitopes whose HLA restrictions require further
confirmation; however their reported allelic restrictions do validate the EpiMatrix results.
The retrospective validation results of 7 of the 20 epitopes are listed in table 9 as an
example; these are the same epitopes whose EpiMatrix results are listed in table 5.
Apart from the positive entries found on IEDB for the 20 selected epitopes that
were tested as 9-mers, negative results were also found for HLA binding assays and/or
CD8+ T-cell assays that contradict with the EpiMatrix predictions. With regard to HLA
binding assays, 4 epitopes were shown to be negative binders of HLA class I alleles
where the negative results contradict with their EpiMatrix scores; despite the fact that all
4 epitopes possess the binding motifs of the supertypes to which those alleles belong.
With regard to CD8+ T-cell assays, entries with “Negative” results for 15 out of the 20
epitopes were found, where the negative result was attributed to the 9-mer itself. For 9
out of those 15 epitopes, the restricting HLA allele associated with the negative response
was determined, and the negative results contradicted with the EpiMatrix binding
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predictions. However, due to the widely varying responses between patient cohorts and
different experimental setups, these negative results cannot be used to rule out those
epitopes from further analysis; further standardized testing is required to draw a final
conclusion.
In addition to the 20 epitopes that have been tested positive as 9-mers, the IEDB
search revealed that 22 out of the 70 chosen epitopes (category 2) had positive entries for
HLA binding and/or the ability to trigger a CD8+ T-cell response as substrings of 10-mer
and/or multimer peptides (>10 AA). HLA binding assay results for these peptides cannot
be used for the validation of the EpiMatrix predictions since they represent the binding
affinities of the 10mer and multimer peptides themselves, and accordingly will not be
considered. Only the results of T-cell assays will be considered, since multimer peptides
undergo processing before presentation on MHC class I molecules. However, since the
optimal epitope size for HLA class I molecules is 9 to 11 AA, the results where the
peptides were tested as 10-mers or where the optimal/minimal epitope has been identified
as a 10-mer are less likely to be attributed to the 9-mer peptide frames harbored within
them as substrings, and hence will not be used as evidence for validation of the EpiMatrix
results. Of the 22 epitopes mentioned herein, only 9 tested positive for the ability to
trigger a CD8+ T-cell response as multimers and had the restricting HLA allele
determined. These results warrant support for further investigation via truncation analysis
in order to identify the optimal/minimal epitope causing the positive response or maximal
stimulation of the CD8+ T-cells. Since in this project only 9-mer binding predictions have
been performed, it is not possible to predict which 9-mer, 10-mer, or 11-mer frame is
responsible for the optimal positive response from within the multimer peptide. The
IEDB search for the remaining 28 of the 70 epitopes (category 3) to which entries were
found in IEDB returned only negative results, which, as aforementioned, cannot be used
to rule out those epitopes from further analysis.
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5.2

HLA Class II Epitope Identification and Validation

5.2.1 iVAX analysis results:
From the 32,286 peptide frames scored by Conservatrix and EpiMatrix for
conservation across the 46 genomes and for binding to the aforementioned DRB1 alleles
respectively, the EpiAssembler tool selected 156 9-mer peptide frames to construct 14
extended ICS peptides, which harbor 9-mer frames in their core sequence that are
collectively conserved in >90% of the analyzed sequences (Open Reading Frame ORF
coverage >90%) and which have a minimum EpiMatrix cluster immunogenicity score of
10. Table 10 lists the results of the EpiAssembler analysis for 5 of the 14 ICS peptides.
The EpiMatrix Z-scores assigned for each of the component 9-mer frames of one ICS
peptide for binding to the analyzed HLA-DRB1 alleles and their percent conservation
calculated by Conservatrix are listed in table 11 as an example. Peptide frames with 4 or
more “hits” are referred to as “EpiBars” and are therefore promiscuous binders. All of the
14 constructed ICS peptides harbor at least one EpiBar.
Analysis of the locations of the ICS peptides revealed that 8 lie in the NS4B
region, 3 in the NS5B region, 1 in the Core region, 1 in the NS3 region, and 1 at the
junction between the NS2 and NS3 protein sequences. JanusMatrix analysis showed that
all of the 14 ICS peptides possess a certain degree of homology to the human genome as
demonstrated by their JanusMatrix cluster scores (table 10). JanusMatrix cluster scores
are equal to the EpiMatrix cluster immunogenicity scores minus penalty deductions for
each cross-reactive match in the human genome for each of the 9-mer component
peptides of the ICS core sequence. The larger the difference between both cluster scores
(EpiMatrix and JanusMatrix), the higher the homology to the human genome. Therefore,
ICS peptides having a smaller difference between both scores are considered better
candidates for inclusion in the final vaccine. Further empirical testing, however, is
required to assess the efficacy and safety of the ICS peptides before deciding on which
ones to include in the final product.
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5.2.2 Retrospective validation results:
The IEDB search revealed that none of the 14 peptides have been tested earlier as
exact sequences, however, all 14 have been previously tested for HLA class II binding
and/or the ability to trigger a CD4+ T-cell response as substring peptides or as peptides
that are 70-99% similar to the ICS peptides (IEDB BLAST 70%-90% search). Of the 14
peptides, 8 have been previously shown (as substrings and/or similar sequences) to
positively bind to different HLA class II alleles via in vitro binding assays; the IEDB
search results for HLA class II binding assays for 4 of these 8 peptides are listed in table
12. Only the results for test peptides that include at least one 9-mer frame from the core
sequence (excluding the 3 AA terminal residues at the N and C termini) of the
corresponding ICS peptide within their core sequence are listed. All binding assays
performed were purified MHC competition binding assays.
With regard to their ability to trigger a CD4+ T-cell response, the IEDB search
revealed that 13 out of the 14 ICS peptides have been previously tested positive in CD4+
T-cell assays (as substrings and/or similar sequences). For only 5 out of the 13, the
restricting HLA class II allele associated with the positive response has been determined;
Table 13 lists the results of the IEDB search for 3 of those 5 ICS peptides; only the
entries where the restricting HLA allele has been determined and where the test peptides
or the empirically-determined minimal epitopes include at least one 9-mer frame from the
core sequence of the ICS peptide within their core sequence are listed. In all of the assays
performed on the 5 ICS peptides, the HLA allelic restriction was determined using
methods 1 and/or 2 mentioned in table 8.
Upon comparing the IEDB results of the 8 aforementioned ICS peptides with the
EpiMatrix predictions, it was found that 39 out of 51 EpiMatrix binding predictions
performed for the component 9-mer frames of the 8 peptides collectively have been
validated as true positive (TP) or true negative (TN). However, 12 binding predictions
had contradicting IEDB results. Further empirical testing must be carried out to confirm
or refute the EpiMatrix predictions before rendering these predictions as false positives
(FP); especially that, for most of the 12 predictions, the contradicting results were
reported in a single corresponding reference. Table 14 lists the results of the retrospective
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validation performed for the ICS peptide NS31246-1265(SQGYKVLVLNPSVAATLGFG)
as an example. For each IEDB entry for HLA binding or T-cell assays performed on the
peptide demonstrated in tables 12 and 13, Table 14 lists whether the HLA restrictions that
tested positive or negative for peptide binding confirm or refute the EpiMatrix predictions
for each of the eight analyzed HLA class II alleles.
Apart from the 8 ICS peptides that have been tested for HLA binding and the
ability to trigger a T-cell response with the restricting allele determined, the remainder 6
peptides were all tested for the ability to trigger a CD4+ T-cell response in previous
literature, and 6 of those tested positive, however without the restricting HLA allele being
determined. These results need to be tested further in the future, and the restricting HLA
class II alleles driving the response need to be determined.

5.3

HLA Class II in vitro binding assay
Table 15 displays the results of the pilot HLA class II binding assay compared to

the highest Z-score calculated by EpiMatrix assigned to one of the core 9-mer frames (the
frame most likely to bind with high affinity to the binding pockets of the HLA class II
molecules). All ICS peptides were found generally to bind with high affinity to the tested
HLA class II molecules, validating the EpiMatrix binding predictions, and confirming the
results of the retrospective validation. This is true except for the peptide NS4B1769–
1786(VSGIQYLAGLSTLPGNPA),

which failed to bind to the allele DRB1*07:01 in

contradiction to the EpiMatrix pedictions. This negative result was also reported from
three different references as shown in table 12 [137-139]. This strongly suggests that the
EpiMatrix binding prediction for this peptide for binding to the DRB1*07:01 allele is a
false positive.
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5.4

Conservation Analysis in newly partially re-sequenced HCV
genomes from the Egyptian population
HCV genomes from 15 serum samples were successfully amplified by RT-PCR;

however, not all 6 regions were successfully amplified in all the extracted genomes.
Table 16 shows 25 genomic fragments from the 15 sequences that were successfully
amplified. The second fragment of NS5B failed to amplify in all serum samples, which
suggests that the sequences of one or both primers targeting that region may have not
been correctly synthesized. Examples of electrophoresis gel photos showing the bands
corresponding to the nested PCR products are shown in figure 16; gel lanes that are not
labeled belong to regions from the HCV sample regions that failed to amplify.
Following amplification, only 23 regions from 14 serum samples were
successfully sequenced in the forward and/or reverse directions, as shown in table 16.
Sample regions K9-NS5B(1) and K10-NS3(2) were not successfully sequenced in neither
the forward nor reverse directions because the amount of DNA amplicons in the samples
was insufficient for performing the sequencing reactions; this insufficiency was probably
due to sample loss by acid hydrolysis upon repeated freeze-thaw cycles and/or during the
purification of the PCR amplicons. Sample region K2-NS5B(1) was successfully
sequenced in the forward direction only. After examining the resulting sequencing
chromatograms of the forward and reverse sequencing reactions performed on the 23
sample regions that were successfully sequenced, it was found that, out of 45 forward and
reverse sequences (excluding the reverse sequence of K2-NS5B(1)), 38 sequences were
found to be of high quality, with clear chromatograms that have low background noise
and distinct sharp peaks for each nucleotide along the sequence (after truncating the low
quality nucleotide peaks at the 5’ and 3’ ends of the sequences). The chromatograms of
the remaining 7 sequences were of low quality with a lot of background noise and broad
peaks along the lengths of the sequences, and accordingly were not carried forward for
further analysis; these 7 sequences, however, had corresponding sequences of the
opposite polarity that were of high quality which were used to determine the amino acid
sequences of the sample regions. The quality of the successfully sequenced samples and
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their sizes after truncation are listed in table 17. Examples of good quality and bad quality
chromatograms are displayed in figure 17.
The results of the BLAST analysis confirmed the identities of most of the high
quality truncated sequences; the highest scoring matches belonged to HCV genotype 4,
with alignment scores > 200 and expect (E) values of 0.0. The BLASTX results of the
sequence K1-NS3(2)-F showed that the sequence was translated into two reading frames
located 10 amino acids apart, with alignment scores > 200 for all aligned results; this
could be due to insertion or deletion mutations that caused a frame shift in the analyzed
sequence probably inserted during the amplification or sequencing reactions. The
BLASTN analysis of the sequences K6-NS3(1)-R, K7- NS3(1)-F, and K7- NS3(1)-R did
not return any results with significant similarity, despite the good quality of the
chromatograms of the truncated sequences that were analyzed; the sequences of those
regions, therefore, were not used for the conservation analysis. Furthermore, BLASTN
analysis of the sequences K8-NS5B(1)-R, K10-NS3(2)-F, and K10-NS3(2)-R showed
that these sequences had matches with sequences from the human genome, suggesting
that samples K8 and K10 were contaminated with human RNA carried over from the
HCV RNA extraction step, which at the low annealing temperatures of the PCR reactions
may have been non specifically amplified.
Following the BLAST analysis, the high quality forward and reverse sequences of
confirmed identities were assembled to derive the consensus sequences of the
corresponding regions. If a mismatch was present between the amino acid sequences of
the forward and reverse fragments, the amino acid residues used for the construction of
the consensus sequence were those matching the corresponding residues of the highest
scoring aligned sequences in the BLAST analysis. The locations of the resultant
consensus amino acid sequences are listed in table 18.
The results of the conservation analysis using the Epitope Conservancy Analysis
tool of the IEDB Analysis Resource website show that, out of 16 HLA class I epitopes in
the NS3 region covered by the consensus sequences, 14 were 100% conserved across the
sequences that harbored them, while 2 were only 50% conserved; the only HLA class II
ICS peptide harbored within that region was also conserved in 100% of the sequences
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that covered it. With regard to the NS4B region, all 14 HLA class I epitopes that were
identified by the in silico analysis were 100% conserved across the sequences that
harbored them, and the same result was reached for 5 HLA class II ICS peptides harbored
within those sequences. As for the Core region, 21 out of the 23 HLA class I epitopes
identified in silico were found to be 100% conserved across the sequences that harbored
them, and only 1 was found to be only 75% conserved; the only ICS class II peptide
located in the Core region was not covered by the new sequences. As for the NS5B(1)
region, none of the NS5B epitopes identified in silico within this region (2 epitopes) were
covered by the new sequences; this is because these epitopes are locate in the 5’ end of
the new sequences which was truncated due to the low quality of the sequencing
chromatograms in that region. Most of the identified NS5B epitopes (13 out of 15 HLA
class I epitopes and 3 HLA class II ICS peptides) are located within the region NS5B(2)
which failed to amplify in all the obtained serum samples.
It is important to note that, as evident from table 17, the number of new sequences
analyzed for each region is not the same. For example, the two HLA class I epitopes that
were found to be only 50% conserved in the NS3 region were only covered by 2 new
NS3 sample region sequences, making them conserved in only 1 of the 2; also, the Core
HLA class I epitope that was found to be conserved in 75% of the sequences was covered
by only 4 new sequences, making it conserved in 3 out of the 4. Generally, the maximum
number of new sequences across which the conservancy of any given epitope was
analyzed was 5, and the minimum was 2. For a pilot study, the results of this
conservation analysis add to the results of the analysis performed by the Conservatix tool
of the iVAX toolkit and confirm the high conservancy of the analyzed epitopes. A larger
number of new sequences from the Egyptian population are required, however, to draw
stronger conclusions about the conservancy of the analyzed epitopes in the HCV RNA
genomes currently circulating in the Egyptian population. If significant deviations from
the conservation analysis results obtained so far are to be found, this will not only
possibly alter the decision of which epitopes are to be included in a population-specific
vaccine for Egypt, but will also indicate the evolution of new HCV strains in the
population that require investigation. An example of the results of the conservation
analysis performed on the new sequences is displayed in table 19.
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6. DISCUSSION
In this project, the immunoinformatics-based identification of a group of highly
conserved and immunogenic T-cell epitopes from the HCV-4 proteome using the
validated iVAX immunoinformatics toolkit was described, as a first step towards the
development of an epitope-driven vaccine that targets HCV-4. A retrospective validation
of the results was also performed using the repository of HCV immune epitope data on
the IEDB; thereby introducing a fast and inexpensive method for the validation of in
silico epitope prediction. The results of the retrospective analysis of 4 HLA class II
constructed ICS peptides were also confirmed by a pilot HLA class II binding assay.
Furthermore, a pilot conservation analysis of the predicted epitopes in the proteomes of
HCV strains currently circulating in the Egyptian population was also performed. Based
on this analysis, a group of 90 HLA class I epitopes and 14 HLA class II ICS peptides
were identified as good putative candidates for vaccine design. A flowchart summarizing
the epitopes’ prediction and selection process and their retrospective validation is
presented in figure 18.
Based on the results of the retrospective validation, 20 out of the set of 90 HLA
class I epitopes were found to have no previous records of empirical testing via HLA
binding assays nor T-cell assays, which warrants support for future research to
investigate their roles in the interplay between HCV-4 and the host immune system, and
to evaluate their efficacy as vaccine targets. From the remaining 70 HLA class I epitopes,
the EpiMatrix prediction results of 19 out of 20 epitopes were validated; where those 20
epitopes were previously tested positive in empirical assays where the test peptides were
the 9-mer epitope sequences themselves. The results of most of the EpiMatrix predictions
for 8 out 14 HLA class II ICS peptides were also validated by retrospective analysis.
These results demonstrate the high accuracy of EpiMatrix as an epitope-mapping tool. In
most of the T-cell assays performed on the class I and II epitopes in previous literature,
the HCV source genotype of the sequences of the test epitopes and the HCV genotype
infecting the human test subjects was either genotype 1 or undetermined; genotypes 2 and
3 were also present as the source or infecting genotypes but to a much lesser extent. This
indicates that the tested epitopes are conserved in HCV genotypes other than HCV-4,
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meaning that they lie in locations in the viral proteins that affect the structure and
function of the protein harboring them and influence the viral life cycle, and hence are
difficult to mutate.
Different kinds of HLA binding assays were performed on the epitopes in
previous literature, the most frequent of which is the purified MHC binding competition
assay, where the binding affinity of the test epitope is measured by determining the
concentration of that epitope required to inhibit the binding of 50% of a labeled standard
epitope to the same purified MHC allele (Inhibitory Concentration 50 [IC 50]) [23]. Cellbound MHC assays have also been performed; these include: (1) a competition assay,
which is similar in concept to the described purified MHC binding competition assay but
with the HLA allele bound to an experimental cell line and not purified [113], (2) a
dissociation (complex stability) assay, where the binding affinity of the test epitope is
measured by determining the time required for it to dissociate from its cell-bound MHC
allele [112], and (3) association assays, where the affinity of the test epitope is quantified
by its ability to associate to and stabilize MHC molecules on the surface of experimental
cell lines compared to controls [105,141-143]. Examples of T-cell assays performed on
the epitopes in previous literature include: (1) Enzyme-linked immunosorbent (ELISA)
and Enzyme-linked immunosorbent spot (ELISPOT) assays, which detect T-cell
responses by measuring cytokine secretion from T-cells (mainly IFN-γ in the IEDB
results) in response to stimulation by the test epitopes [23], (2) cytotoxicity assays, which
detect the cytotoxic (lytic) response of CD8+ T-cell to target cells displaying the test
epitope on their surface by measuring the release of a marker, usually the radioisotope
Chromium 51, from the lysed target cells [105], (3) MHC tetramer staining assays, where
streptavidin-labeled tetrameric constructs of MHC alleles in association with the test
epitope are used to detect and quantify the amount of T-cells in a given blood sample that
are specific for that epitope [144], (4) intracellular cytokine staining (ICS) assays, where
the T-cell response is measured by detecting cytokines produced intra-cellularly in
response to stimulation by the test peptide via intra-cellular cytokine staining followed by
flow cytometry for visualization [23], and (5) proliferation assays, where the T-cell
response is detected by measuring the proliferation of those T-cells in response to
stimulation by the test epitope [23].
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When the locations of the identified HLA class I and II epitopes were mapped on
the HCV polyprotein sequence, it was found that most epitopes are located within the
Core, NS3, NS4B, and NS5B regions. Within the Core protein region, which is the
building block of the viral capsid, 23 class I epitopes and one class II ICS peptide were
identified. Within the NS3 protein region, 21 class I epitopes and one class II ICS peptide
were identified. Within the NS4B protein region, 14 HLA class I epitopes and 8 HLA
class II ICS peptides were identified, and finally within the NS5B region, 15 HLA class I
epitopes and 3 class II ICS peptides were identified. Due to the important structural and
functional roles that these proteins play in the HCV life cycle, it is difficult for the virus
to mutate those sequences at low fitness costs, which explains why the biggest proportion
of the conserved epitopes identified in this project was located within those regions.
Furthermore, a large group of those epitopes was also found to be conserved in other
HCV genotypes, as demonstrated by the retrospective validation results performed on
IEDB. This does not only demonstrate the importance of those epitopes’ sequences in the
HCV life cycle, but also means that these epitopes provide excellent targets for a crossgenotype effective vaccine. On the other hand, in the E1 and E2 regions, very few highly
conserved epitopes were identified relative to the sizes of those regions, which is
explained by the hypervariable nature of those proteins required for the virus to escape
recognition from the humoral immune system.
In order to avoid triggering a suppressive or autoimmune response to the final
vaccine product, the novel JanusMatrix tool was used to assess the homology of the
analyzed epitope set to the human genome; epitopes with several cross-reactive hits with
epitopes derived from the human genome are better to be excluded from the final
product. In this project, a highly stringent selection of HLA class I epitopes that had 0
cross-reactive hits in the human genome was performed. The same could not be done for
the HLA class II ICS peptides, which all had some degree of homology to the human
genome; if 9-mer peptide frames within the ICS peptides were to be removed to decrease
this degree of homology, the promiscuous coverage of the HLA-DR alleles provided by
the peptides, their ability to bind to HLA class II molecules, and their HCV-4 subtype
coverage would all be compromised. Here it is important to note that when a large set of
empirically characterized T-effector cell epitopes were analyzed by JanusMatrix, it was
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found that a T-cell epitope homologous to the human genome may still be able to
successfully trigger a T-effector cell response if that degree of homology lies within a
certain ratio of cross-reactive hits per number of AA residues in the human genome
database [84]. Therefore, future empirical analysis of the kind of responses the HLA class
II ICS peptides can trigger is required before deciding on which epitopes to include in the
vaccine. While JanusMatrix is efficient in identifying homologous epitopes derived from
the human genome, it cannot identify all of the putatively cross-reactive epitopes. This is
because, in reality, the TCRs of cross-reactive T-cells can recognize their target epitopes
by the conformational availability of their AA side-chain residues and not just their exact
sequence identity. However, JanusMatrix can still provide a preliminary prediction of
cross-reactivity based on sequence identity that can narrow down the selection of
epitopes which would be later tested empirically for the nature of the immune response
that they can trigger [84]. Work is currently still in progress to establish a normalized
scoring scheme for JanusMatrix (similar to EpiMatrix Z-score) to define a threshold
based on which the nature of the analyzed epitopes (whether effector or suppressive) can
be determined.
The conservation analysis performed on the newly partially re-sequenced HCV
genomes isolated from the Egyptian population showed that almost all the epitopes
located within the new sequences were fully conserved across them. This indicates that
these epitopes may provide good coverage of the HCV strains currently circulating in the
Egyptian population, which makes them good candidates for a vaccine that can be
effective in Egypt; however, the number of sequences included in the analysis is
relatively small, which decreases the power of the conclusions drawn from the analysis.
From the small amount of serum samples that could be obtained to carry out the analysis,
not all regions were successfully amplified; which could be attributed to low viral loads
in the samples, mismatches between the HCV RNA and the amplification and sequencing
primers, and/or the degradation of the HCV RNA with repeated freeze-thaw cycles.
Furthermore, HCV RNA is known to have a relatively high GC content, meaning that 2ry
RNA structures may have been difficult to denature at the low primer annealing
temperatures employed in the reactions. All the above factors may have contributed to the
decrease in availability of enough HCV RNA templates to perform the RT-PCR
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amplification. This is supported by the fact that, for the sample regions that did amplify, a
relatively large volume of extracted HCV RNA was required to carry out the reactions at
low optimal annealing temperatures. Better results can be obtained in the future by
determining the viral load of the analyzed sequences prior to amplification so as to only
use samples with high viral loads, and by using primer sequences that are designed based
on only the HCV-4 strains derived from the Egyptian population.
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7. CONCLUSION
HCV-4 is the predominant HCV genotype in the Middle East and Africa; in
Egypt, the country with the highest HCV infection rates worldwide, more than 90% of
the infections are attributed to the same genotype. Despite the direness of the issue, very
limited attention has been given to HCV-4 as a vaccine target in HCV vaccine research.
In an attempt to fill this gap in research, this project describes the in silico identification
and selection of a group of highly conserved and immunogenic T-cell epitopes from the
HCV-4 proteome as a first step for the development of an epitope-driven vaccine against
HCV-4. The iVAX immunoinformatics toolkit was used to identify the epitopes; where
its epitope prediction tool, EpiMatrix, was proven to be of the most accurate epitope
prediction tools available online. The in silico results were retrospectively validated using
the repository of empirical HCV immune epitope data on the IEDB; thus demonstrating
the accuracy of EpiMatrix as a prediction tool, and the conservation of the identified
epitopes across other HCV genotypes. This retrospective method of validation can
provide a fast and inexpensive alternative to performing empirical validations from
scratch for different strains of previously investigated pathogens, such as HCV, HIV,
Influenza, or Coronaviruses. The method can be useful when designing populationspecific or personalized vaccines and/or in the case of an outbreak caused by a new strain
of a given pathogen. In addition to identifying and retrospectively validating the epitopes,
the HCV-4 subtype sequence coverage provided by the identified epitopes for the HCV
strains circulating in the Egyptian population has been investigated, as a pilot assessment
of the putative efficacy of the vaccine when used in Egypt.
In the future, empirical characterization of the 20 novel HLA class I epitopes
identified by the iVAX analysis must be carried out, and further assessment of the
efficacy of the retrospectively validated HLA class I and class II T-cell epitopes as
vaccine targets in patient populations where HCV-4 prevalence is high needs to be
pursued. Pre-clinical trials for previously thoroughly investigated epitopes using small
animal models can be directly undertaken. In the coming years, several new drugs for
HCV treatment will enter the market, just like the recently approved drug Sofobuvir.
These drugs, although they hold promise for increasing the rates of treatment success,
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remain very expensive for patient populations in the Middle East and Africa. The
development of an effective vaccine targeting those populations will have a strong impact
on HCV therapy and prophylaxis.
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8. TABLES
Table 1: HCV Structural & Non-Structural Proteins and their functions. A summary of the roles
that HCV proteins play in the HCV life cycle [12].

Protein
Core
E1 & E2

Function
Forms the viral nucleocapsid.
Mediate viral attachment to cell-surface receptors and fusion of viral and cellular
membranes in the viral entry step of the HCV life cycle.

p7

Cation channel (viroporin), essential for assembly and release of infectious HCV
particles.

NS2

Constitutes the cis-acting auto-protease together with NS3 for cleavage of the NS2NS3 junction in the precursor polyprotein molecule.

NS3

A multi-functional protein. The N-terminal one-third harbors a serine protease
catalytic domain that catalyzes cleavage of the polyprotein molecule at the NS2/NS3,
NS3/NS4A, NS4A/NS4B, NS4B/NS5A, and the NS5A/NS5B junctions with the aid of
the NS4A co-factor. The C-terminal two-thirds of the protein harbor an RNA
helicase/NTPase, which is suggested to unwind extensive secondary RNA structures
during RNA replication.

NS4A

Co-factor of NS3 serine protease activity.

NS4B

Induces formation of the membranous web, the site of HCV RNA replication in the
host cell

NS5A

Modulates the efficiency of viral RNA replication

NS5B

RNA-dependant-RNA polymerase, catalyzes viral RNA replication
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Table 2: HCV Vaccines in Clinical Trials. Examples of HCV vaccines currently undergoing clinical trials, and the results of these trials as reported
so far [17].
Phase
Vaccine Type, Components, Source HCV
(Year)
& Investigator Company genotype

Tested subjects

Outcome

Notes

Recombinant protein
E1/E2 protein + MF59C
adjuvant
(Novartis Inc.)

1a

I (2010)

60 healthy subjects Safe and elicited antibody In pre-clinical trials it elicited antibody and T-cell
and T-cell responses in all responses in 21 chimpanzees: 5 developed sterilizing
subjects.
immunity against a homologous challenge with HCV1a, and 14 managed to clear the challenge virus after
infection [57].

Peptide Vaccine
IC41: 5 peptides from Core,
NS3, and NS4 regions
+ poly-L-arginine adjuvant
(Intercell AG)

1 and 2

II (2008)

60 patients,
chronic HCV-1
infection, HLA-A2
positive

Safe, induces T-cell
response in 67% of
patients, and caused
decrease in viremia >1
log in 3 subjects.

A new phase II clinical trial for the vaccine has been
started in 2011 testing the effects of the vaccine in
combination with the new broad spectrum antiviral
Nitazoxanide.

DNA Vaccine
ChonVac-C: plasmid
expressing NS3/4a protein
(Tripep AB)

N/A

I/IIa
(2009)

12 treatmentnaive patients
infected with HCV1

Safe, caused >0.5 log
decrease in viral load in
4/6 patients who
received higher doses

Delivered by electroporation to enhance intramuscular
injection immunogenicity.

Vector Vaccine
TG4040: Modified vaccinia
Ankara (MVA) vector
expressing NS3,4, and 5B
proteins
(Transgene)

N/A

I (2009)

15 patients with
Chronic HCV

Caused 0.5–1.4 decline in Phase II trial planned in combination with standard
viral load in 6/15
therapy.
patients.
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Table 3: Analyzed HCV-4 Sequences. A List of the 46 HCV IV full genomes whose corresponding
polyprotein amino acid sequences were uploaded to the iVAX server for epitope prediction and
analysis.
Accession
Number

Genotype/Subtype

DQ418782
DQ418783
DQ418784
DQ418785
DQ418786
DQ418787
DQ418788
DQ418789
DQ516083
DQ516084
DQ988073
DQ988074
DQ988075
DQ988076
DQ988077
DQ988078
DQ988079
EF589160
EF589161
EU392169
EU392170
EU392171
EU392172
EU392173
EU392174
EU392175
FJ025854
FJ025855
FJ025856
FJ462431
FJ462432
FJ462433
FJ462434
FJ462435
FJ462436
FJ462437
FJ462438
FJ462439
FJ462440
FJ462441
FJ839869
FJ839870
GU814265
HQ537008
HQ537009
NC_009825

4a
4a
4a
4
4d
4a
4a
4a
4d
4a
4a
4a
4a
4a
4a
4a
4a
4f
4f
4f
4f
4K
4d
4k
4f
4f
4b
4b
4b
4p
4g
4m
4q
4b
4c
4d
4k
4r
4o
4n
4t
4l
4a
4v
4v
4a

RNA
Sequence
Length
9292
9253
9298
9218
9273
9307
9306
9295
9300
9309
8957
9054
9057
9051
9043
9050
8965
9181
9304
9309
9269
9281
9299
9312
9298
9297
9267
9242
9271
9475
9435
9425
9433
9440
9468
9421
9438
9440
9422
9435
9488
9388
9497
9174
9177
9355

Protein ID
ABD75824
ABD75825
ABD75826
ABD75827
ABD75828
ABD75829
ABD75830
ABD75831
ABF60956
ABF60957
ABL63005
ABL63006
ABL63007
ABL63008
ABL63009
ABL63010
ABL63011
ABU68271
ABU68272
ACB45490
ACB45491
ACB45492
ACB45493
ACB45494
ACB45495
ACB45496
ACL68400
ACL68401
ACL68402
ACS29430
ACS29431
ACS29432
ACS29433
ACS29434
ACS29435
ACS29436
ACS29437
ACS29438
ACS29439
ACS29440
ACT66294
ACT66295
ADF97233
AEI00316
AEI00317
YP_001469632
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Amino Acid
Sequence
Length
3009
3008
3008
2985
3007
3008
3008
3008
3006
3009
2899
2932
2933
2931
2928
2932
2902
2969
3010
3009
3009
3011
3006
3011
3009
3009
3010
3011
3011
3009
3008
3006
3010
3011
3022
3006
3011
3011
3005
3008
3007
3006
3008
2973
2974
3008

Sampling
Country
U.S.A.
U.S.A.
U.S.A.
U.S.A.
U.S.A.
U.S.A.
U.S.A.
U.S.A.
Spain
Spain
Egypt
Egypt
Egypt
Egypt
Egypt
Egypt
Egypt
France
France
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Portugal
Portugal
Portugal
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Canada
Egypt
Cyprus
Cyprus
Egypt

Reference

[87]

[88]

Direct
Submission

[89]

[90]

[91]

[20]

[92]
[93]
[94]

Table 4: RT-PCR and Sanger Sequencing primers. The polarity of the primers is denoted in subscript letters (F: Forward, R: Reverse). Nested
primers are denoted by the subscript letter ‘N’; not all nested primers have a nested counterpart of opposite polarity.
Forward Primers

Reverse Primers
o

Primer

Primer Sequence (5' - 3')

Location

AF

TGATAGGGTGCTTGCGAGTGC

294 - 314

21

59.7

BF
BFN
CF
CFN

YGGCAGGGACACCAAYGA

3485 - 3502

18

56.3

GTACACCAATGTTGACCARGA

3641 - 3661

21

50.9

ATCATCTGTGACGARTGCCA

4278 - 4297

20

53.3

GTCCTGGACCAAGCGGARAC

4335 - 4354

20

56.8

CAGTTTGACGAAATGGARGARTG

5451 - 5473

23

56.5

TGYTGCTCAATGTCATAYTCATGGAC 7596 - 7621

26

59.8

22

58.1

DF
EF
FF

ATGAYACCCGCTGCTTTGACTC

8257 - 8278

Length (nt) Tm ( C) Primer

Primer Sequence (5' - 3')

Location

Length Tm (oC)

Amplicon
Target Region
size

AR
ARN

TGCTKGAATTCGGGCAGTCRTT

954 - 975

22

62

679 bp

CACGAGAGAAGTGCCAARAGGAAGAT

867 - 892

26

60.9

599 bp

BR

AGGGCGACCTCCTCTATRTT

4422 - 4441

20

53.7

CR
CRN

GCTGACATACAAGCCATGATGTAYTT

5268 - 5293

26

57.3

1016 bp

CACTTCCACATGGTGTCCCA

5151 - 5170

20

56

836 bp

DR
DRN
ER
ERN

TTTAGCCACGTYTTGAAGTCA

6308 - 6328

21

52.8

878 bp

GTCTGARAAGGGATGTCACAGT

6195 - 6216

22

50.6

766 bp

ACRTAGAGTCTYTCTGTGAGGGC

8364 - 8386

23

54.3

791 bp

TCGGGCTCCAGGTCACA

8327 - 8343

17

55.1

752 bp

GRTTGAGTTCGTGTGGAGAGTATCC

9027 - 9051

25

57.9

793 bp

FR

76

957 bp
801 bp

Core

NS3 (1)

NS3 (2)

NS4B

NS5B (1)
NS5B (2)

Table 5: Binding prediction results for 7 HLA class I candidate epitopes for HCV-4 vaccine
design. The dark blue color code of the EpiMatrix Z-sores indicates that the epitope is from
amongst the top 1% binders of that allele in a random set of peptides, the blue color indicates
that the epitope is from amongst the top 5% binders, and light blue color code indicates that the
epitope is from amongst the top 10% binders. Z-scores of the bottom 90% binder peptides are
not highlighted. The ‘Hits’ column displays the number of HLA alleles each epitope is predicted
to bind to with a Z-score ≥ 1.64 as a measure of the epitopes’ binding promiscuity.
EpiMatrix Z-Scores

Epitope
Sequence

Percent
Conservation

A*01:01

A*02:01

A*03:01

A*24:02

B*07:02

B*44:03

DVVCCSMSY

0.98

2.52

-0.14

2.42

0.19

-0.21

RLLAPITAY

0.98

1.86

1.07

2.64

0.09

FWAKHMWNF

0.96

-0.21

-0.01

-0.54

QYLAGLSTL

1

-0.5

0.95

DPRRRSRNL

0.98

-1.56

YLVAYQATV

0.93

ITYSTYGKF

0.93

Hits

Location

0.6

2

NS5A/NS5B

0.93

2.02

3

NS2/NS3

3.11

1.16

0.97

1

NS4B

-0.69

2.73

0.55

1.13

1

NS4B

-1.12

-1.46

0.45

2.81

-0.49

1

Core

0.71

3.2

0.6

0.27

0.56

0.76

1

NS3

1.75

0.37

1.24

1.4

1.49

1.27

1

NS3
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Table 6: IEDB Results for HLA Class I Binding Assays performed on 4 candidate epitopes for
HCV-4 vaccine design. The “Quantitative Measure” column displays the quantitative results of
the HLA binding assays, where: (1) the IC50 results of competition binding assays are displayed in
nanomolar concentrations (nM), and (2) the results for the HLA dissociation assay are displayed
in minutes. The “Assay Result” column displays the designated relative binding affinity of the
epitopes as determined by the authors based on the quantitative results of the assays where
available, or as determined by the IEDB curators.
AA Sequence

Restricting
Allele

Quantitative
Measure

Assay Result

Ref.

DVVCCSMSY

A26

Purified MHC - Radioactivity Competition

25 nM

Positive

101

RLLAPITAY

A*03:01

Purified MHC - Radioactivity Competition

4 nM

Positive - High

102

YLVAYQATV

A*02:01

Purified MHC - Radioactivity Competition

45 nM

Positive - High

103

45 nM

Positive - High

104

20 nM

Positive - High

105

20 nM

Positive - High

102

20 nM

Positive - High

106

20.4 nM

Positive

107

20.4 nM

Positive - High

108

5 nM

Positive - High

109

N/A

Positive

110

59 nM

Positive - Intermediate

111

Cell bound MHC - Fluorescence Dissociation

1440 min.

Positive - High

112

Cell bound MHC - Fluorescence Competition

4.8 nM

Positive - High

113

Purified MHC - Radioactivity Competition

39.1 nM

Positive - High

108

4.3 nM

Positive - High

109

5.2 nM

Positive - High

109

Cell bound MHC - Fluorescence Competition

1.5 nM

Positive - High

113

Purified MHC - Radioactivity Competition

15.9 nM

Positive - High

108

10 nM

Positive - High

109

Cell bound MHC - Fluorescence Competition

2.1 nM

Positive - High

113

Purified MHC - Radioactivity Competition

4.3 nM

Positive - High

109

22.6 nM

Positive - High

109

82.2 nM

Positive - Intermediate

108

3.7 nM

Positive - High

109

15 nM

Positive - High

113

A*02:02

A*02:03

A*02:05

A*02:06

Assay Description

Purified MHC - Radioactivity Competition

Cell bound MHC - Fluorescence Competition
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Table 6: Continued.

FWAKHMWNF

A*02:07

Purified MHC - Radioactivity Competition

> 2300 nM

Negative

109

A*68:02

Purified MHC - Radioactivity Competition

33.3 nM

Positive - High

108

40 nM

Positive - High

109

Cell bound MHC - Fluorescence Competition

81 nM

Positive - Intermediate

113

Cell bound MHC - Fluorescence Association

N/A

Positive

105

A*24:02
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Table 7: IEDB Search Results for T-cell Assays performed on 4 candidate epitopes for HCV-4
vaccine design. “N/A” HCV genotype means that the genotype of the source or infecting virus
was undetermined. The Method of Restricting Allele Determination column is explained in table
9.
AA Sequence

Restricting
HLA Allele

Ref.

T-cell Assay
Description

Assay
Result

Source
HCV
Genotype

Patient(s)
HCV
Genotype

Method of
Restricting
Allele Determination

DVVCCSMSY

A26

101

ICS (IFN-γ)

Positive

1

1

1C

114

ICS (IFN-γ)

Positive

1

1

1B

108

51

N/A

N/A

3C

115

Cytotoxicity Assay

Positive

1

N/A

3B

116

Cytotoxicity Assay

Positive

1

N/A

3B

117

ELISpot (IFN-γ)

Positive

1

N/A

3B

118

ELISpot (IFN-γ)

Positive

1

N/A

3A

102

51

Cr Release Cytotoxicity Positive

N/A

N/A

2C

111

51

Cr Release Cytotoxicity Negative

1

N/A

3C

119

ELISpot (IFN-γ)

Negative

1

N/A

3B

120

ELISpot (IFN-γ)

Negative

1

N/A

3C

121

MHC Tetramer Staining
ELISpot (IFN-γ)

Positive

1

1

2A

122

MHC Tetramer Staining

Positive

N/A

N/A

2

105

51

1

1

3C

123

ELISpot (IFN-γ)

1

1

3B

124

51

N/A

1

1B

125

ELISpot (IFN-γ)

1

N/A

3B

YLVAYQATV

A2

A*02:01

FWAKHMWNF A*24:02

DPRRRSRNL

B7

Cr Release Cytotoxicity Positive

Cr Release Cytotoxicity Positive
Positive

Cr Release Cytotoxicity Positive
Positive
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Table 7: Continued
126

51

127

ELISpot (IFN-γ)

128

ELISpot (IFN-γ)

Cr Release Cytotoxicity Positive

81

N/A

N/A

3B

Positive

1

N/A

3B

Negative

1

N/A

3B

Table 8: Restricting HLA allele determination. Methods of restricting HLA allele determination
of T-cell assays listed in table 8.

Method of Restricting Allele Determination
1

T-cell assay performed on CD8+ T-cells from HLA-X+ individuals utilizing different
APCs with matched and mismatched HLA alleles to demonstrate allelic restriction

2

T-cell assay performed on CD8+ T-cells from HLA-X+ individuals utilizing APC or HLA
tetramers presenting the peptide where the is only a single type of HLA present to
demonstrate allelic restriction

3

T-cell assay performed on CD8+ T-cells from HLA-X+ individuals utilizing APCs that
are HLA-X+ presenting the test epitope on their surface

Basis for prediction/knowledge of Restriction
A

In silico binding prediction / Contain HLA binding motif

B

Cited reference

C

In vitro binding assay
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Table 9: Retrospective validation results of 7 predicted HLA class I epitopes. The Z-scores of
the supertype alleles whose binding predictions were retrospectively validated are emphasized
by an underline and in bold red font.
AA
Sequence

EpiMatrix Z-Scores

Empirically demonstrated
A*01:01 A*02:01 A*03:01 A*24:02 B*07:02 B*44:03 HLA restrictions (Supertype)

Prediction
Validated?

DVVCCSMSY

2.52

-0.14

2.42

0.19

-0.21

0.6

A26 (A01)

Yes

RLLAPITAY

1.86

1.07

2.64

0.09

0.93

2.02

A*03:01 (A03)

Yes

ITYSTYGKF

1.75

0.37

1.24

1.4

1.49

1.27

A*24:02 (A24)

Yes (top 10%)

YLVAYQATV

0.71

3.2

0.6

0.27

0.56

0.76

A*02:01 (A02)
A*02:02 (A02)
A*02:03 (A02)
A*02:05 (A02)

Yes

A*02:06 (A02)
A*68:02 (A02)
FWAKHMWNF

-0.21

-0.01

-0.54

3.11

1.16

0.97

A*24:02 (A24)

Yes

QYLAGLSTL

-0.5

0.95

-0.69

2.73

0.55

1.13

A*02:01 (A02)

No

DPRRRSRNL

-1.56

-1.12

-1.46

0.45

2.81

-0.49

B7 (B07)

Yes
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Table 10: Five Immunogenic Consensus Sequence peptides constructed by EpiAssembler. The
9-mer frames of the core of the ICS peptides are emphasized in the ICS sequence column. The
Open Reading Frame (ORF) coverage column displays the percentage of the HCV-4 sequences
covered by each ICS peptide with regard to the conservation of its 9-mer core frames,
collectively, across the sequences analyzed.
EpiMatrix
Cluster Score
35.24

Janus Matrix
Cluster Score
14.23

Location

Region

SQGYKVLVLNPSVAATLGFG

ORF
Coverage
1

1246 - 1265

NS3

VSGIQYLAGLSTLPGNPA

1

18.78

4.58

1769 - 1786

NS4B

ICS Sequence

STQQTLLFNILGGWVAAQI

1

11.32

2.23

1802 - 1820

NS4B

EGAVQWMNRLIAFASRGNHVA

1

23.46

19.42

1910 - 1930

NS4B

PTIWVRMILMTHFFSILQXQE

0.98

24.91

19.03

2837 - 2857

NS5B
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Table 11: Component 9-mer frames of the ICS peptide NS31246-1265 (SQGYKVLVLNPSVAATLGFG). The table illustrates the Conservatix and
EpiMatrix scores of each overlapping 9-mer frame in the peptide. Z-score color codes follow the same rules stated in table 6. Epibars (9-mer
frames that have 4 or more ‘hits’) are highlighted in yellow.
9-mer
Frame

EpiMatrix Z-Scores
Percent
Hits
Conservation DRB1*01:01 DRB1*03:01 DRB1*04:01 DRB1*07:01 DRB1*08:01 DRB1*11:01 DRB1*13:01 DRB1*15:01

SQGYKVLVL

0.02

-0.08

-0.37

0.14

0.89

0.26

-0.08

1.1

0.45

0

QGYKVLVLN

0.98

-1.14

-0.83

-1.37

-0.81

0.73

-0.66

-0.37

-1.09

0

GYKVLVLNP

0.98

-0.45

-0.47

0.36

0.15

-0.6

0.24

-0.11

-0.69

0

YKVLVLNPS

0.98

1.81

1.93

2.02

1.43

2.6

3.08

1.35

2.1

6

KVLVLNPSV

1

1.59

0.97

1.31

1.33

0.87

1.61

1.26

1.9

1

VLVLNPSVA

1

1.9

1.39

1.73

1.48

1.31

1.74

1.49

1.58

3

LVLNPSVAA

1

2.15

2.04

2.28

1.76

1.6

1.59

2

1.77

6

VLNPSVAAT

1

0.62

0.02

1.15

0.41

0.35

0.64

0.9

0.19

0

LNPSVAATL

1

1.97

1.83

1.39

1.9

0.82

1.45

1.68

1.38

4

NPSVAATLG

1

0.22

-0.39

0.08

-0.69

-0.18

-0.65

-0.18

-0.06

0

PSVAATLGF

1

-0.51

0.19

0.67

0.24

-0.34

-0.29

0.32

-0.25

0

SVAATLGFG

1

-0.44

0.95

-0.35

-0.68

0.85

0.22

-0.17

1.05

0
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Table 12: IEDB Search Results for HLA Class II Binding Assays performed on 4 ICS peptides. The
“Test Sequence” column lists the peptide sequence actually tested by the authors of the listed
references; AA residues identical to the ICS sequence are colored in black, mismatched residues
are colored in red and are underlined, AA residues outside the ICS frame are faded in grey. The
“IC50” column displays the results of the purified MHC competition binding assays in nanomolar
concentrations (nM).
ICS Sequence

Test Sequence

SQGYKVLVLNPSVAATLGFG

GYKVLVLNPSVAAT

Restricting
Allele

IC50

Assay Result

132 DRB1*01:01

1.4

Positive -High

133 DRB1*04:01

7.8

Positive -High

DRB1*04:04

33

Positive -High

DRB1*04:05

141

Positive -Int

DRB1*07:01

126

Positive -Int

DRB1*08:02

21

Positive -High

DRB1*09:01

266

Positive -Int

DRB1*11:01

75

Positive -High

DRB1*13:02

3.5

Positive -High

DRB1*15:01

39

Positive -High

DRB1*08:03

1124

Negative

DRB1*12:01

4604

Negative

DRB5*01:01

Ref.

3695

Negative

GYKVLVLNPSV

134 DRB1*11:01

26

Positive -High

GYKVLVLNPSVAATL

135 DRB1*04:01

N/A

Positive

KVLVLNPSVAATLGF

136

DR1

8

Positive -High

DR4

20

Positive -High

DR7

7

Positive -High

DR11

390

Positive

DR15

210

Positive

AQGYKVLVLNPSVAATLGFGAYMSKAHGID 136

86

DRB5

447

Positive

DR3

4183

Negative

DR13

10000

Negative

DRB3

40000

Negative

DRB4

6481

Negative

DR4

5

Positive -High

DR15

57

Positive -High

DR11

40

Positive -High

DR7

15

Positive -High

DR1

1

Positive -High

DR13

900

Positive -Low

DRB5

1225

Negative

DR3

2500

Negative

Table 12: Continued.
DRB3

>100000

Negative

DRB4

2449

Negative

137 DRB1*01:01

3.5

Positive -High

DRB1*04:01

9.7

Positive -High

DRB1*07:01

23

Positive -High

DRB1*08:02

80

Positive -High

DRB1*09:01

20

Positive -High

DRB1*11:01

240

Positive -Int

DRB1*13:02

4.1

Positive -High

DRB1*15:01

42

Positive -High

DRB5*01:01

8154

Negative

EGAVQWMNRLIAFASRGNHVA GEGAVQWMNRLIAFASRGNHV 137 DRB1*01:01

3.2

Positive -High

DRB1*04:01

361

Positive -Int

DRB1*07:01

221

Positive -Int

DRB1*08:02

158

Positive -Int

DRB1*11:01

14

Positive -High

DRB5*01:01

182

Positive -Int

DRB1*09:01

6818

Negative

137 DRB1*01:01

8.7

Positive -High

DRB1*11:01

88

Positive -High

DRB1*04:01

5328

Negative

DRB1*07:01

6305

Negative

138 DRB1*01:01

13

Positive -High

DRB1*04:01

698

Positive -Int

DRB1*04:04

35.9

Positive -High

DRB1*15:01

3.03

Positive -High

DRB1*03:01

92.5

Positive -High

137 DRB1*01:01

10

Positive -High

DRB1*04:01

84

Positive -High

DRB1*08:02

70

Positive -High

DRB1*09:01

441

Positive -Int

DRB1*11:01

74

Positive -High

DRB5*01:01

606

Negative

DRB1*07:01

>10000

Negative

2.9

Positive -High

DRB1*04:01

3

Positive -High

DRB1*15:01

99.2

Positive -High

DRB1*04:04

1.97

Positive -High

DRB1*03:01

>70000

Negative

135 DRB1*04:01

N/A

Positive

138 DRB1*04:01

13.2

Positive -High

GYKVLVLNPSVAATLGFGAY

GPGEGAVQWMNRLIAFASRG

GAVQWMNRLIAFASRGNHVS

VSGIQYLAGLSTLPGNPA

NFISGIQYLAGLSTLPGNPA

QYLAGLSTLPGNGN

GIQYLAGLSTLPGNPAIASL
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138 DRB1*01:01

Table 12: Continued.
DRB5*01:01

357

Positive -Int

DRB1*15:01

365

Positive -Int

DRB1*11:01

5.31

Positive -High

DRB1*04:05

6.28

Positive -High

DRB1*13:02

214

Positive -Int

DRB1*01:01

0.946

Positive -High

DRB1*07:01

2180

Negative

DRB1*03:01

35000

Negative

139 DRB1*01:01

1

Positive -High

DRB1*04:01

13

Positive -High

DRB1*04:05

6

Positive -High

DRB1*11:01

5

Positive -High

DRB1*13:02

214

Positive -Int

DRB1*15:01

378

Positive -Int

DRB5*01:01

357

Positive -Int

DRB1*03:01 >69767

Negative

DRB1*07:01

2176

Negative

STQQTLLFNILGGWVAAQI LTTSQTLLFNILGGWVAAQL 138 DRB1*15:01

17.4

Positive -High

DRB1*07:01

638

Positive -Int

DRB1*04:05

502

Positive -Int

DRB1*13:02

101

Positive -Int

DRB1*01:01

2.5

Positive -High

DRB1*04:01

2470

Negative

DRB5*01:01

1950

Negative

DRB1*11:01

12300

Negative

DRB1*03:01

3920

Negative
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Table 13: IEDB Search Results for CD4+ T-cell Assays performed on 3 ICS peptides. The “Test/Optimal Sequences” column lists the peptide
sequences actually tested by the authors or the optimal sequence within the tested peptides responsible for the maximal T-cell response
(denoted by an asterix*) as shown by truncation analysis. Methods of restricting allele determination follow the same rules of table 9.
ICS Sequence

Ref.

SQGYKVLVLNPSVAATLGFG

141

3

QGYKVLVLNPSVAATLGFGA

Source
Genotype
N/A

Subjects
Genotype
N/A

MHC Tetramer staining

GYKVLVLNPSVAAT

N/A

MHC Tetramer staining

GYKVLVLNPSVAATL

H -thymidine cell proliferation

GYKVLVLNPSVAAT

Assay

Test/Optimal Sequences

H -thymidine cell proliferation

135
132

3

DRB1*11:01

Method of Restricting
Allele Determination
1B

N/A

DRB1*11:01

2B

N/A

N/A

DRB1*04:01

2B

1,2

1, N/A

DRB1*12:01

1C

Restricting Allele

DRB1*11:01
DRB1*13:02
DRB1*04:01
DRB1*16:01
141
142

3

144

3

MHC Tetramer staining

GYKVLVLNPSVAATL

N/A

N/A

DR4

2B

H -thymidine cell proliferation

VLVLNPSVAATLGFGAYM

N/A

N/A

DRB1*04:01

2

QYLAGLSTLPGN*

N/A

3

DRB1*11:04

1

MWNFISGIQYLAGLSTLPGN

1

3

DRB1*11:01

LAGLSTLPGNP*

1

1

DRB1*04:01

Cytokine Release (IL-2)
VSGIQYLAGLSTLPGNPA

H -thymidine cell proliferation

139

ICS (IFN-γ)

1C

DRB1*11:04
DRB1*04:07
DRB1*04:04
141

MHC Tetramer staining

SGIQYLAGLSTLPGNPAIASL

N/A

N/A

DR4

2B

MHC Tetramer staining

SGIQYLAGLSTLPGNPAIASL

N/A

N/A

DRB1*04:01

2C

H–thymidine cell proliferation

LFNILGGWVA*

N/A

1,3

DRB1*01:01

1

FNILGGWVAAQL

N/A

1,3

DRB1*01:01

Cytotoxicity Assay
135
STQQTLLFNILGGWVAAQI

144

3
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Table 14: Retrospective validation results of ICS peptide NS31246-1265 (SQGYKVLVLNPSVAATLGFG).
True positive (TP) and false positive (FP) assignments validate or refute the EpiMatrix binding
predictions outlined in table 12. Cells without assignments lack corresponding empirical data for
comparison.
Type
of Assay

HLA Binding
Assay

CD4+ T-cell
Assay
Overall
Results

Validation Results
DRB1*01:01 DRB1*03:01 DRB1*04:01 DRB1*07:01 DRB1*08:01 DRB1*11:01 DRB1*13:01 DRB1*15:01
TP

---

TP

TP

TP

TP

TP

TP

---

---

---

---

---

TP

---

---

---

---

TP

---

---

---

---

---

TP

FP

TP

TP

---

TP

---

TP

TP

---

TP

TP

TP

TP

TP

TP

---

---

---

---

---

TP

---

---

---

---

TP

---

---

---

---

---

---

---

TP

---

---

TP

TP

---

---

---

TP

---

---

---

---

---

TP

FP

TP

TP

TP

TP

TP

TP
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Table 15: HLA Class II binding assay results. The binding affinity scale is divided as follows: (1)
Strong Binder: IC50 < 10,000 nM, (2) Moderate Binder: 10,000 < IC50 <100,000 nM, (3) Weak
binder: IC50 > 100,000 nM.
ICS Sequence

DRB1*01:01
DRB1*04:01
DRB1*07:01
Highest
Highest
Highest
IC50 (nM)
IC50 (nM)
IC50 (nM)
Z-Score
Z-Score
Z-Score

DRB1*15:01
Highest
IC50 (nM)
Z-Score

SQGYKVLVLNPSVAATLGFG

2.15

44

2.28

123

1.9

3,010

2.1

711

VSGIQYLAGLSTLPGNPA

2.54

148

2.25

694

1.93

Non-binder

2.25

1,239

STQQTLLFNILGGWVAAQI

2.33

215

1.94

721

1.77

122,087

1.6

782

EGAVQWMNRLIAFASRGNHVA

2.54

2,726

1.52

20,416

1.55

44,713

2.56

103

91

Table 16: Amplified and Sequenced HCV Samples from the Egyptian Population. “Amp” means
that the region of the corresponding sample was successfully amplified by RT-PCR and Nested
PCR. “Seq” means that the region was successfully sequenced in the forward and/or reverse
directions.
Sample
K1
K2
K3
K4
K5
K6
K7
K8
K9
K10
K11
K12
K13
K14
K15

Core
--------------------Amp + Seq
Amp + Seq
Amp + Seq
Amp + Seq
---

NS3 (1)
--Amp + Seq
--Amp + Seq
--Amp + Seq
Amp + Seq
----Amp + Seq
-----------

NS3 (2)
Amp + Seq
Amp + Seq
Amp + Seq
Amp + Seq
Amp + Seq
--------Amp Only
-----------
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NS4B
--Amp + Seq
--Amp + Seq
Amp + Seq
------------Amp + Seq
Amp + Seq
-----

NS5B (1)
--Amp + Seq
----------Amp + Seq
Amp Only
------Amp + Seq
--Amp + Seq

NS5B (2)
-------------------------------

Table 17: Egyptian population successfully sequenced sample regions’ sizes, chromatogram qualities, and locations on the HCV polyprotein
sequence. The letters “F” and “R” in the sample region column label the forward and reverse sequences obtained from the sequencing
reactions. The translation reading frames of the sequences were determined using the BLASTX analysis. The locations of the translated amino
acid sequences on the reference HCV-1a (H77) AA sequence were determined using the Sequence Locator tool of the HCV Los Alamos database.
Sample
K1

K2

K3

K4

K5

K6
K7

Sample
Region
NS3(2)-F
NS3(2)-R
NS3(1)-F
NS3(1)-R
NS3(2)-F
NS3(2)-R
NS4B-F
NS4B-R
NS5B(1)-F
NS5B(1)-R
NS3(2)-F
NS3(2)-R
NS3(1)-F
NS3(1)-R
NS3(2)-F
NS3(2)-R
NS4B-F
NS4B-R
NS3(2)-F
NS3(2)-R
NS4B-F
NS4B-R
NS3(1)-F
NS3(1)-R
NS3(1)-F
NS3(1)-R

Chromatogram Quality
High
Low
High
High
High
High
Low
High
High
--High
High
High
Low
Low
High
High
High
High
High
High
High
Low
High
High
High

Length after
Truncation (nt)
741
--633
616
680
738
--568
651
--751
781
632
----570
693
659
766
781
678
674
--443
464
541
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Reading
Frame
+1/+3
--+1
-1
+1
-2
---3
+3
--+1
-1
+3
-----1
+2
-2
+1
-1
+2
-1
--N/A
N/A
N/A

Location on HCV polyprotein (AA)
1354 – 1486 / 1497 - 1599
--1152 - 1362
1111 - 1315
1358-1578
1352 - 1596
--1717 - 1904
2447 - 2662
--1354 - 1603
1337 - 1596
1151 - 1359
----1354 - 1543
1724 - 1952
1717 - 1935
1349 - 1603
1337 - 1596
1730 - 1954
1709 - 1927
--N/A
N/A
N/A

Table 17: Continued.
K8
K10
K11

K12

K13

K14
K15

NS5B(1)-F
NS5B(1)-R
NS3(2)-F
NS3(2)-R
Core-F
Core-R
Core-F
Core-R
NS4B-F
NS4B-R
Core-F
Core-R
NS4B-F
NS4B-R
NS5B(1)-F
NS5B(1)-R
Core-F
Core-R
NS5B(1)-F
NS5B(1)-R

Low
High
High
High
Low
High
High
High
High
High
High
High
High
High
High
High
High
High
High
High

--407
478
487
--392
503
503
695
704
504
505
619
688
650
652
469
502
676
679
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--N/A
N/A
N/A
---1
+3
-2
+1
-3
+1
-1
+1
-3
+3
-1
+3
-2
+2
-3

--N/A
N/A
N/A
--1 - 117
14 - 180
1 - 155
1746 – 1952
1710 - 1943
14 -180
1 – 155
1739 - 1944
1708 - 1924
2450 – 2664
2422 – 2637
25 - 179
1 - 155
2443 – 2665
2426 - 2650

Table 18: Consensus assembled HCV sequences and their locations.
Sample

Region

K1

NS3(2)

Location (AA)
1354 – 1486
1497 - 1599

NS3

1111 - 1596

NS4B

1717 - 1904

NS5B(1)

2447 - 2662

NS3(2)

1337 - 1603

NS3

1151 - 1543

NS4B

1717 - 1952

NS3(2)

1337 - 1603

NS4B

1709 - 1954

Core

1 - 117

Core

1 - 180

NS4B

1710 - 1952

Core

1 - 180

NS4B

1708 - 1944

NS5B(1)

2422 - 2664

K14

Core

1 - 179

K15

NS5B(1)

2426 - 2665

K2
K3
K4
K5
K11
K12

K13
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Table 19: Example of the conservation analysis results across the newly partially re-sequenced
HCV genomes from the Egyptian population. The “Sequence Coverage” column displays the
number of sequences in which the epitopes were conserved as part of the total number of new
sequences that cover their locations.
Location
Region
(AA)
HLA Class I Epitopes
YLVAYQATV
1585 - 1593
NS3
ITYSTYGKF
1291 - 1299
NS3
FWAKHMWNF
1760 -1768
NS4B
RPMDVKFPG
18 - 26
Core
HLA Class II ICS Peptides
SQGYKVLVLNPSVAATLGFG
1246 - 1265
NS3
VSGIQYLAGLSTLPGNPA
1769 - 1786
NS4B
STQQTLLFNILGGWVAAQI
1802 - 1820
NS4B
EGAVQWMNRLIAFASRGNHVA 1910 - 1930
NS4B
Epitope Sequence
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Sequence
Coverage

% Conservation

4/4
1/2
5/5
3/4

100%
50%
100%
75%

2/2
5/5
5/5
4/4

100%
100%
100%
100%

9. FIGURES

Figure 1: HCV Entry into Hepatocytes. Schematic representation of our current understanding
of the viral entry step in the HCV life cycle. Reprinted by permission from Macmillan Publishers
Ltd: Nature Reviews Microbiology [12], copyright 2007.
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Figure 2: HCV RNA and Polyprotein. Schematic representation of the HCV RNA genome, the
precursor polyprotein molecule, and its processing into the structural and non-structural
proteins of HCV. Reprinted from [12]. Reprinted by permission from Macmillan Publishers Ltd:
Nature Reviews Microbiology [12], copyright 2007.
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Figure 3: HCV Proteins. Schematic representation of the structures of the HCV proteins and
their ER membrane associations. Reprinted from [12]. Reprinted by permission from Macmillan
Publishers Ltd: Nature Reviews Microbiology [12], copyright 2007.
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Figure 4: Type I and III IFN production. Detailed schematic depiction of how HCV induces the
production of type I and III IFNs by triggering intracellular signaling pathways that lead to their
expression. Reprinted with permission from [29].
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Figure 5: Maturation of Dendritic Cells. Schematic representation of the uptake of HCV antigens
by immature dendritic cells (iDCs), and their subsequent maturation into myeloid dendritic cells
(mDCs); which in turn activate naïve T-cells in the lymphoid organs. Reprinted from [40] with
permission from Elservier.
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Figure 6: The Evolution of the T-cell response to HCV. Graphical illustration of the changes in
viral and T-cell titers across the 3 phases of the T-cell response to HCV; and the possible
outcomes of infection: a) weak, short-lasting T-cell response ending in viral persistence, b)
initially strong T-cell response that is not sustained, ending in viral persistence, and c) Strong and
sustained T-cell response ending in viral clearance. Reprinted with permission from [43].
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Figure 7: Inhibition of IFN production and ISG protein action. Schematic representation of the
interference of different HCV proteins with the expression of type I IFNs and ISG and with the
actions of the ISG protein products; the interference of HCV proteins is emphasized in red.
Reprinted with permission from [14].
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Figure 8: Suppressive actions of T-regulatory lymphocytes. Schematic illustration of the
mechanisms by which Tregs suppress the immune response: a) via inhibitory cytokines, b)
triggering apoptosis, c) metabolic disruption, and d) inhibition of DC maturation. Reprinted by
permission from Macmillan Publishers Ltd: Nature Reviews Immunology [51], copyright 2008.
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Figure 9: HCV evasion of neutralizing antibodies. Schematic illustration of how HCV evades
recognition and capture by neutralizing antibodies. Reprinted with permission from [15].
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Figure 10: The interaction between HCV and the host immune system. A schematic illustration
of the immune response to HCV in the acute phase of the infection, and the mechanisms by
which HCV evades that response to lead the infection to progress to the chronic phase.
Reprinted with permission from [17].
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Figure 11: The HLA class II binding groove. A 3-dimentional model of the binding groove of an
HLA class II molecule bound to an epitope. The side chains of the amino acid residues P1, 4, 6,
and 9 are anchored in the pockets of the binding clefts. Reprinted by permission from Macmillan
Publishers Ltd: Nature Reviews Immunology [67], copyright 2006.
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Figure 12: The EpiMatrix frequency matrix for the Class I HLA allele A*02:01. The colors in the
grid represents the frequency that a given amino acid residue is observed at a specific amino
acid position in a large set of natural HLA-A*02:01 epitopes. The color “Red” indicates the amino
acid is frequently present at that position, and therefore promotes epitope binding to the HLA
molecule when present. “Blue” indicates the opposite. Reprinted with permission from [62].
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Figure 13: Construction of an Immunogenic Consensus Sequence peptide by EpiAssembler.
First, EpiAssembler identifies the most highly conserved epitope across the analyzed sequences
and the one that is most promiscuously immunogenic, which here is SIVNRVRQG (an X denotes a
mismatch with the conserved peptide), the program then identifies overlapping highly
conserved and promiscuously immunogenic peptides, and then assembles those peptides into
an extended ICS. Reprinted with permission from [23].
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Figure 14: The two faces of the T-cell epitope. A 3D model of a T-cell epitope in association with
an HLA molecule and a T-cell receptor, with the ‘epitope’ residues facing the TCR, and the
‘agretope’ residues facing the HLA molecule. Reprinted with permission from [84].
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Figure 15: Primer Alignment. An example of the alignment of the primer AF with the 46 HCV-4
sequences using the ClustalX 2.1 software.
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Figure 16: HCV RNA amplification results. Examples of electrophoresis gel photos presenting
the results of the nested PCR amplification reactions for 11 sample regions are displayed. The
results were analyzed on a 1% agarose gel, with 5 μL of a 100 bp DNA Ladder (Promega, WI,
USA) loaded into the first well of each gel, and 5 μL of each of the sample regions amplicons
added to the other wells; all mixed with 2 μL loading dye. The gel was then run at 95V for 1 hour
in 1X TBE running buffer, and the amplicon bands were visualized on an ECX-20.M
transilluminator (Vilber Lourmat, Marne-la-Vallée, France). Images of the gels were taken using
a Samsung S2 8.0 megapixel mobile phone camera (Samsung, Seoul, South Korea).
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Figure 17: Sequencing Chromatograms Qualities. An example of a high quality sequencing
chromatogram is illustrated at the top (part of the sequencing chromatogram of sample region
K2-NS3(1)-F) with sharp peaks and low background noise. An example of a low quality
chromatogram is illustrated at the bottom (part of the sequencing chromatogram of sample
region K2-NS4B-F) with high background noise.
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Figure 18: Flowchart summarizing the performed in silico T-cell epitope prediction and
retrospective validation process.
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